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ABSTRACT 
The effects of carnitine supplementation on AFB 1 toxicity in male Sprague-Dawley 
rats were studied. Rats were fed Purina Rat Chow with or without camitine supplement 
for 6 weeks. In Experiment 1, the rats (n=20) were dividetinto 4 groups, namely . 
nonsupplemented control (NSC), nonsupplemented AFB 1 (NSA), camitine supplemented 
control (CSC) and camitine supplemented AFBl (CSA) groups. The NSA and CSA 
groups were given an oral dose of [3H]AFB 1 ( 1 mg/kg) 6 h before sacrificing. In 
Experiment 2, the rats (n= 10) were divided into NSA and CSA groups and were sacrificed 
24 h post-AFB 1 administration. Concentrations of total lipid, triglycerides, camitine and 
AFB I -macromolecules adduct formation, and urinary excretion of AFB 1 were measured. 
Carnitine supplementation prevented increase in hepatic total lipid and triglyceride 
concentrations caused by AFB 1. In the plasma, supplemental camitine prevented the 
AFB I-induced decrease in the .¥11ount of total lipid and triglyceride. Carnitine 
supplementation reduced AFB 1 covalent binding to hepatic macromolecules, namely �� A, 
DNA, and protein. The c,:mcentrations of RNA, DNA, and protein in the CSA rats were 
significantly higher than in the NSA animals 24 h post-AFB 1 treatment. [3H]AFB I 
radioactivity was found in the acid insoluble acylcamitine (AIAC) fraction. Carnitine 
supplement, however, had no significant effect on the amount of [3H]AFB 1 associated 
with AIAC. AFB 1 treatment of rats 6 h prior to sacrifice caused significant increase in the 
liver nonesterified camitine (NEC), acid soluble acylcarnitine (ASAC), and total camitine. 
The amounts of AFB! in the liver, kidney and plasma were not significantly different in the 
NSA and CSA animals. The concentration of AFB 1 excreted in the urine was also not 
statistically differe_nt in the CSA and NSA rats. In conclusion, carnitine supplemention 
offered protection against AFB I-induced fatty liver and AFB I-macromolecule adducts 
formation. 
iv 
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CHAPTER 1 
INTRODUCTION 
Aflatoxins, a group of secondary metabolites of Asper�llus flaYlll and.A. 
parasiricus, are often found to contaminate food and feed supplies. Epidemiological studies 
and clinical findings especially in developing countries such as Uganda (1 ), Kenya, 
Swaziland, Mozambique, and Thailand (quoted from 2) showed incidences of liver cancer 
correlated to consumption of aflatoxin-contaminated food. In India, acute toxicity of 
aflatoxins due to consumption of aflatoxins-contaminated maize affected 397 patients, of 
which, 106 died (3). Analysis on the maize samples showed that the patients might have 
consumed 2 to 6 mg of aflatoxins per day for several weeks. Recently, acute toxicity of 
aflatoxins have been reported as the cause of deaths of eleven children in Malaysia who ate 
rice noodles that were contaminated with aflatoxins ( 4). 
Aflatoxin B 1 (AFB 1) is the most abundant and toxic of all aflatoxins. It has been 
found to be hepatotoxic (5), hepatocarcinogenic (6), and teratogenic (7). AFB1 in 
. combination with other aflatoxins has been reported to be immunosuppresive (8). The liver 
is the main target organ of aflatoxin toxicity. The signs of liver damage caused by AFB 1 
include fatty liver, bile duct hyperplasia, and finally necrosis (9). 
Fatty liver is also caused by acute and chronic alcohol intoxication in animals and 
humans (10, 11, 12) which has been attributed to increase lipogenesis and/or impaired fatty 
acid oxidation. Camitine, a vitamin-like substance whose main function is in 
intramitochondrial transport of fatty acids for beta-oxidation, has been shown to ameliorate 
ethanol-induced fatty livers in rats (13, 14, 15). Therefore, it was thought desirable to 
examine if camitine supplement could prevent the fatty liver caused by AFB 1 . 
2 
AFB 1 needs to be activated by mixed function oxygenase system to fonn an AFB 1 -
epoxide which can covalently bind to electrophilic centers (N, 0, and S atoms) of 
macromolecules such as DNA, RNA, and protein (2). These covalent bindings, especially 
to the DNA have been linked to AFBt carcinogenicity. Since carnitine has a electrophilic N 
center, it is possible that AFB 1-epoxide could bind to camitine, and in doing so, spare the 
macromolecules from the electrophilic attack of AFB1. Camitine has been reported to 
lessen the side-effects of therapeutic drugs (16) via conjugation to the drugs (17). 
In light of these observations, the following objectives were setforth for this study: 
1 . To detennine the effects of supplementary camitine on AFB 1-induced fatty liver; 
2. To study the effects of supplementary carnitine on AFB 1-macromolecules 
binding; 
3. To determine of effects of AFB 1 on plasma and liver carnitine concentrations and 
[3H]AFB 1 associated with carnitine. 
3 
CHAPTER 2 
REVIEW OF LITERATURE 
2. 1 AFLATOXINS 
2, 1. 1 History 
Aflatoxins are a group of secondary metabolites of Asperiillus flayus and A.. 
parasiticus. These mycotoxins are often found to contaminate food and feeds (such as 
milk, com, peanuts, cottonseed, rice, barley, and many others) as well as grain-fermented 
beverages and edible animal tissues (18). These toxins have been considered as 
unavoidable contaminants since they cannot be totally eliminated or prevented from 
contaminating food or feeds even with the most modem technology available today (19). 
The problem of aflatoxin contamination has long been recognized and limits or action levels 
for the toxin content in agricultural commodities have been set since 1965. 
Aflatoxins were first discovered in 1960 when a series of outbreaks in poultry and 
fish occurred in different parts of the world. One of the worst outbreaks was known as a 
"turkey X" disease which had caused many deaths of turkeys and ducklings in the United 
Kingdom due to consumption of contaminated Brazilian peanut meal ( quoted from 9). The 
acute symptoms of the disease included weakness, loss of appetite, lethargy, and 
"distinctive attitude of the head and neck" at the time of death. Histologically, the disease 
caused an acute liver necrosis and bile duct proliferation. Consumption of contaminated 
com, peas and cotton-seed had also been reported as the cause of outbreaks analogous to 
the turkey X disease in farm animals and fish (quoted from 9). 
4 
In 1961, Sargeant et al. (20) isolatedA � from the contaminated Brazilian 
peanut meal. The investigators found that when the fungus was reinoculated into peanut 
meal, it produced toxins similar to those found in the contaminated Brazilian meal. The 
name "aflatoxins" (AF) was given to the toxins that had been extracted and isolated The 
letters B and G refer to the toxin's color under UV light (B--Blue; G--Green), and the 
subscripts relate to their position on thin-layer chromatography plates. Currently, over a 
dozen aflatoxins have been identified. 
2.1.2 Structure and Toxicity Differences of Aflatoxins 
Aflatoxin B1(AFB1), B2 (AFB2), Gt (AFGt) and G2 (AFG2) are the four major 
naturally occuring aflatoxins. The structure of aflatoxins consists of a coumarin nucleus 
attached to a bifuran and either a pentanone (AFB 1 and AFB2) or a six-membered lactone 
(AFGt and AFG2) (refer to Figure 2.1). AFMt, AFM2, AFGMt, and AFGM2 are the 
!Detabolites produced in microbial and/or animal systems when they are exposed to the 
above naturally occuring aflatoxins (22). AFB1 and AFGt were found to be more toxic to 
rats and ducklings than AFB2 and AFG2 (23). As for carcinogenicity, AFBt was more 
potent than AFG 1, which in turn, was more carcinogenic than AFB2 (24 ). 
Hydroxy lated derivatives of aflatoxins are AFM 1, AFM2, AFGM 1, AFB2a, 
AFG2a, parasiticol, aflatoxicol, AFPt, and AFQ1. The toxicity of AFM1 is similar to 
AFBt but less carcinogenic. AFG2a is relatively non-toxic, and it has been identified as 
AFB 1 hemiacetal, aflatoxin W (AFW) and hydroxydihydroaflatoxin (9). Parasiticol 
(AFB3) has an ethanol moiety in place of the terminal pentanone ring. It is as toxic as 
AFB 1 to duckling but less toxic than AFB 1 to chick embryos . Aflatoxicol (A.Ro) is a 
degradation prcxluct of AFB.I and has been found to be highly toxic and carcinogenic to 
fish (24). 
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AFP1 is produced when AFB1 undergoes 0-demethylation in animals. AFP1 LD50 
· value to mice is about 15 times less than that of AFB 1 (25). AFQ1, which contains a 
hydoxyl group at the C-3 position, has been isolated in vitro using monkey and human 
liver microsomes (25,26). Aflatoxin D1 and D2 are two major degradation products of 
AFB 1 when detoxified with ammonia. 
2. 1 .3 AFB1 Metabolism 
The metabolism of AFB 1, in vivo or in vitro, may result in many different 
derivatives of the toxins. In vitro, AFB 1 undergoes at least five types of metabolic 
reactions with liver enzyme preparations, namely reduction, hydroxylation, hydration, 0-
demethylation and epoxidation (see Figure 2.2) (22,27). The products of the respective 
reactions are aflatoxicol, AFM1, AFQ1, AFB2a, AFP1, and AFB1-2-3 -oxide. Except for 
the epoxide, all the metabolites contain an OH- group which can be conjugated with 
glucuronic acid and sulfate. This conjugation results in detoxification of the aflatoxins by 
the formation of water-soluble aflatoxin esters which can be excreted in the urine or bile 
(22). 
AFB 1 requires metabolic activation by mixed-function oxygenase (MFO) system to 
form the epoxide derivative that is responsible for AFB 1 toxicity and carcinogenicity (22). 
Once formed, the epoxide can either cause an electophilic binding on nucleophiles (such as 
nucleic acids and proteins); or be conjugated with reduced gluthathione and be detoxified; 
or be hydrolyzed to form the 2, 3-dihydrodiol of AFB 1; or be reduced to the hemiacetal 
form (22). 
The major adduct formed between AFB1 and DNA and RNA has been identified as 
the 2, 3 -dihydro-2-(N7-guanyl)-3 -hydroxy-AFB1 (28). The covalent binding of AFB 1 to 
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macromolecules DNA, RNA, protein) has been suggested as the main mode of acute 
toxicity and carcinogenicity of AFB1 (22) .  The half-life of AFB1-DNA adducts is reported 
to be approximately 12  h, after which they are rapidly excreted in the urine (29). 
2.1 .4 Toxicity and Carcinogenicity of AFB1 
AFB 1 is the most toxic, most abundant, and therefore, the most studied of all 
aflatoxins. It constitutes about 75% of the aflatoxins found in naturally contaminated 
agricultural commodities (22) .  It has been reported to be hepatotoxic (5), 
hepatocarcinogenic (6), teratogenic (7), mutagenic (30), and immunosuppressive (8). The 
liver is the main target organ for AFB1 toxicity and carcinogenicity. However, AFB 1 has 
been found to cause tumors in kidneys of rats (31 ). 
The acute toxicity of AFB 1 has been shown to cause severe morbidity and deaths in 
laboratory (5) and farm (9) animals, and humans (3,4) (refer to Table 2. 1 for LD50 of 
AFB l on different animals). The covalent binding of AFB1 with DNA was linearly 
correlated with the susceptibility of animals such as rats and trout to liver cancer (32). It 
has been documented to have carcinogenenic effects on mice, rats (23), ducks (33), trout 
(24) and primates (6). A number of epidemiological studies have also shown a strong 
correlation between dietary aflatoxin consumption and liver cancer rates in humans ( 1 , 2, 
29, 32) (see Table 2.2.) Virtual safe dose of aflatoxin in human was estimated to be 0.264 
ng/kg/d or less (32) .  
2. 1,4,a Species and Gender Differences 
Metabolism of AFB 1 in different species of animals may produce different 
metabolites of AFB 1 . As a result, the susceptibility to acute toxicity and carcinogenicity of 
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Table 2. 1 Median Lethal Dose of AFB 1 .  
Species mg/kg, oral 
Rabbit 0. 3 
Duckling 0. 3 
Cat 0 .6 
Pig 0.6 
Trout 0. 8 
Dog 1 .0 
Guinea Pig 1 .4 
Sheep 2.0 
Monkey 2.2 
Mouse 9.0 
Hamster 10.2 
Chick 1 1 .5 
Male Rat 7 .2  
Female Rat 17 .2 
Source: Marasas et al. (1987) . Aflatoxicosis . In: Mycotoxicology: Introduction to the 
Mycology, Plant Pathology, Chemistry, Toxicity, and Pathology of Natural Occuring 
Mycotoxicosis in Animals and Man. pp. 25-31 ,  Pennsylvania State University Press, 
University Park, PA. 
Table 2.2 Aflatoxin Ingestion and Liver Cancer Incidence in Humans. 
Cases o( liver cancer in adults ( > 15 years old) 
Dietary 
ana,o"in Men Women 
intake 
(ng,kg or SoJl00.000 NoJI00.000 
body weight population population 
Population per day, per year Incidence per year Incidence 
Kenya 
High alti1ude 3-5 I 3. 1 0 0 
:vf edium ahitude (>-8 1 3  1 0.8 6 3.3 
Low altitude 10-15 1 6  1 2.9 9 5.4 
Swaziland 
Highveld 5-9 9 7.0 2 1 .4 
Middleveld 9-14 24 14.8 5 2.:? 
Lebombo 1 5-20 4 1 8.7 o . 0 
Lowveld 43-53 35 26.7 7 5.6 
Thailand• 
Songkh:ila 5-8 
Ratburi 45-77 
Moumbique" :?:?:? 35.0 15.7 
Nor�: Data were compiled for I ye:ir in Thailand. 3 ye:ics in Mozambique. and 4 ye:irs in K�nya :ind Swaziland. 
• Statistics for the total popul:i1ion were c:ises per I 00.000 population wi1h an incidence of 6.0. In Ra1buri. Thailand. 
staliMics for the 101al population were two cases per 100.000 popul:i1ion per ye:ir with an incidence of 2.0. 
• Incidence for che to1al popul:ition was ZS.4 cases per 1 00.000 population per ye:ir. 
Source: Groopman et al. (1988). Aflatoxin exposure in human populations: 
Measurements and relationships to cancer. In: CRC Critical Reviews of Toxicology, 
Volume 19, Issue 2, pp. 1 1 3-145. 
1 1  
AFB 1 varies from species to species. Also, the liability of acute toxicity and 
carcinogenicity are not dependent on one another (9). 
Rats were found to be highly susceptible to carcinogenic effects but moderately 
susceptible to acute toxicity of AFB 1 . On the other hand, guinea pigs were more 
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susceptible to acute effects but less susceptible to carcinogenic effects (34). Monkeys were 
relatively resistant to carcinogenic effects of AFB 1 but were quite sensitive to acute effects 
compared to rats and mice. Also, of the three species, monkeys had the lowest AFB 1 
excretion rate, and mice were quite resistant to both acute and carcinogenic effects (35). 
AFB 1-binding to liver RNA and protein was higher in guinea pigs than rats. This 
corresponds with the higher susceptibility of guinea pigs than rats to acute toxicity of 
AFB 1 . In addition, the lower AFB 1-DNA binding in guinea pigs than in rats indicates that 
rats are more susceptible to the carcinogenic action of AFB 1 . Mice had the lowest AFB 1-
macromolecule adducts formation which comsponded to their resistance to both acute and 
carcinogenic effects (36). 
Male rats have higher AFB1-DNA binding than female rats which indicates that 
female rats are relatively resistant to carcinogenic action of AFB 1 (37). It was suggested 
that the increase in induction of detoxification enzymes in females rats, may have a 
protective effect on AFB 1 toxicity. In humans, cases of acute aflatoxicosis were twice as 
many in males than in females (3). 
2. 1.4,b Symptoms of Acute Aflatoxicosis 
The general symptoms of acute aflatoxicosis in cattle, dogs, pigs, and poultry were 
decrease in weight, general unthriftiness and inappetence .(38). Signs of liver injury 
include icterus, edema, hemorrhage, and ascites. Death rates are usually high and may be 
preceeded by convulsions and ataxia. Histopathological studies on livers of laboratory 
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animals showed fatty degeneration, necrosis, fibrosis, and extensive bile-duct proliferation 
(38). In humans, symptoms of acute aflatoxicosis due to consumption of contaminated 
maize included vomitting, anorexia, icterus, ascites, and sometimes edema. Death usually 
occurred after massive gastrointestinal hemorrhage (3). Similar symptoms were also seen 
in dogs that had eaten the contaminated maize. 
2.1 .4.c AFB1 and Lipids Metabolism 
AFB 1 has often been reponed to interfere with lipid metabolism in both animals and 
humans. Lipid synthesis was inhibited in ducklings (39) and chickens ( 40) due to AFB 1 . 
In ducklings, the toxin significantly suppressed growth and lowered liver weigl"a, but it 
increased total lipids content in the liver. The toxin showed a dose-dependent inhibition of 
lipids synthesis by reducing the incorporation of 14c-acctate into long-chain fatty acids in 
chickens ( 40). Triglycerides, total phospholipids, and free and esterified cholesterol in 
chicken's blood serum were significantly lowered with a dose of aflatoxin that was too 
small to inhibit growth. However, liver lipids were significantly increased ( 41 ). 
In rat liver, AFB 1 increased cholesterol levels while inhibiting cholesterol synthesis 
(42). The investigators suggested that the inhibition of cholesterol synthesis was specific 
and not the result of general hepatic injury. Serum cholesterol levels were significantly 
decreased. Phospholipids synthesis was also inhibited in liver preparation of rats 
previously injected with aflatoxin (43). 
Aflatoxins have been found to cause steatorrhea in chickens. Pancreatic lipase, 
primary fat digestive enzyme, and bile, important for lipid digestion and absorption, were 
decreased significantly in this case. The authors concluded that the steotorhea was due to 
impairment in lipid digestion produced by the aflatoxins added to the diet (44). 
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AFB 1 had also attenuated lipids synthesis in humans. Using human skin 
specimens, Black et al. (45) found that incorporation of radio-labeled acetate into total 
lipids, phospholipids, free sterol, and neutral fat was significantly inhibited. The authors 
also suggested that the inhibition was specific and not due to general liver toxicity. 
Overall, the investigators that studied the effects of aflatoxins on lipid metabolism 
concluded or suggested that i) the increase in liver lipids and decrease in serum lipids was 
due to inhibition of lipid transport from the liver to the blood and peripheral tissues and not 
. due to increase in lipogenesis (39,42); ii) the inhibition was general and not specific to 
lipid fractions ( 41 ); iii) the impairment in lipogenesis was due to a decrease in the formation 
of enzymes involved in fatty acid biosynthesis such as fatty acid synthetase ( 40). 
2, 1 .5 AFB I -Macromolecule Adducts and Diet/Dru� Interactions 
Many studies have been carried out to determine the effects of various food/nutrients 
and drugs/xenobiotics on the AFB 1-macromolecule addu�ts formation. The major 
objective of these investigations was to find if the nutrients and drugs/xenobiotics could 
inhibit the adducts formation, and thus, preventing the carcinogenic effects of AFB 1. 
2. 1,5.a Food Nutrients 
Fat-Soluble Vitamins 
Quite a range of vitamins and vitamin analogs that have been tested on AFB 1-
macromolecule adducts formation. Bhattacharya et al. have reported comprehensive 
studies on the effects of various vitamins on in vitro adducts formation ( 46) and AFB 1 
mutagenicity ( 47). 
Vitamin A supplementations in rats inhibited AFBl -DNA adducts formation (48). 
The protective effects of retinoids such as retinol, retinal, retinoic acid, and retinyl esters on 
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AFB 1 carcinogenicity was due to inhibition of ON A adducts formation mediated by 
microsomal MFO enzymes (46,49). Retinol had the same inhibitory effect on the 
formation of AFB 1-protein adducts ( 49). As for mutagenicity, retinol, and retinoic acid 
were shown to inhibit mutagenesis due to AFB1 in the Salmonella typhimurium system 
(47,50). It was suggested that the protective effects of vitamin A were the result of 
interaction with microsomal enzymes; resulting in interference with the activation of AFB 1 
(47,49). Recently, vitamin A has been shown to be imponant in regulating gluthathione-S­
transferase (GST) activity involved in the detoxification process. Vitamin A 
supplementation increased the GST activity and the reverse occurrcd when vitamin A was 
deficient (48). 
Vitamin E supplementation had no significant effect on in vivo covalent binding of 
AFB 1 to liver macromolecules in rats. However, a combined deficiency of vitamin E and 
selenium decreased DNA, RNA, and protein adducts in the rats (5 1 ). Yet, the same 
investigators reported that the combined deficiency of vitamin E and selenium increased the 
DNA and RNA adducts in chicks (quoted from 5 1). Vitamin E, as well as menadione, a 
water soluble synthetic vitamin K, both inhibit AFB 1-induced mutagenisis in Ames 
bacterial system (50). 
w arer-Soluble Vitamins 
Riboflavin, rifboflavin-5'-phosphate (FMN), and flavin adenine dinucleotide (FAD) 
inhibited AFB I -DNA adduct formation in vitro (46). Riboflavin being more effective than 
FMN and FAD. Vitamin C, vitamin B6 and thiamin had no significant effect on the DNA 
adducts production (46). However, vitamins C, B6, B 12 and folic acid significantly 
inhibit mutagenisis in bacterial systems (46,47). The inhibition by vitamin C; however, 
was not as great compared to fat-soluble vitamins. 
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Amino Acids and Protein 
A diet marginally deficient in methionine (which was also deficient in choline and 
lacking in folacin) depressed DNA and RNA adducts formation in rat liver. Protein adduct 
was not affected by the diet. The inhibition of AFB 1-nucleic acid adducts by the 
marginally lipotrope-deficient diet was due to the decrease in :MFO activities and not due to 
an increase in gluthathione levels (52). The authors concluded that the earlier reported 
AFB 1 -induced tumorigenesis caused by marginally deficient lipotrope diets (53) was not 
due to an increased in activation of AFB 1 . 
Sulfur-containing amino acids such as cysteine, N-acetylcysteine, cystint�, 
methionine, and reduced or oxidized gluthathione inhibited AFB 1 mutagenicity in microbial 
systems. Cysteine and N-acetylcysteine were more potent inhibitors than gluthathione. 
The investigators suggested that the inhibition was due to the amino acids interfering with 
the activation of the AFB1 (54) . 
..Eal 
Both saturated and unsaturated dietary fats did not significantly affect the adduct 
formation and the production of the AFB1-cpoxide in rat livers (55). In a similar study, 
high polyunsaturated oil (com oil) increased the incidence of liver ·cancer in rats exposed to 
AFB 1 as compared to rats fed with saturated oil (beef fat). The cancer incidence was 
higher when the com oil was fed together with or after the exposure to AFB 1 than when 
corn oil was fed after the AFB 1 dose. An increase in induction of AFB 1 activation by com 
oil was suggested for the high incidence of cancer (56). 
The presence of long chain fatty acids at their physiological concentrations increased 
the strength of AFB 1 -albumin binding considerably (57). Albumin serves as the major 
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transpon mechanism of AFB 1 in blood since very little AFB 1 was bound to other blood 
proteins (58). This binding affinity (Ka) is increased 3 fold by increasing the pH from 6 to 
9. The presence of palmitic, stearic, and oleic acids (the most abundant plasma fatty acids) 
at the concentration range of 0.5 to 2.0 moles/mole albumin funher increased the albumin 
binding of AFB 1 to greater than 4 fold at pH 7 .4 (57). 
Trace elements 
Copper decreased AFB1-DNA binding in vitro (46). Deficiency and excess of 
selenium decreased the adducts formation in rats. In chicks, however, excess of selenium 
did not affect the amount of adducts formed (51). 
Copper, manganese, zinc, and selenium were effective in depressing in vitro 
mutagenesis induced by AFB 1 . Copper was the most potent of the elements tested. To a 
lower extend, icxline, molybdenum, cobalt, and iron were antimutagenic. It was suggested 
that the inhib�on was due to interaction of the trace elements with the microsomal enzymes 
(59) . 
2. 1 .5 .b Caloric Restriction 
There has been considerable interest on the effect of caloric restriction on cancer 
promoting chemicals and compounds. It has been reported that rats fed with 60% of the 
food consumed by the ad libitum animals had lower AFB 1 microsomal activation, lower 
AFB 1 -DNA adducts, faster plasma clearance, and increased excretion of AFB 1 in urine 
than the ad libitum fed animals. From these results, the authors concluded that 40% food 
restriction promoted a more efficient AFB 1 metabolism ( 60). 
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2, 1,5,c Cruciferous Ye�etables 
Cruciferous vegetables have been shown to enhance detoxification of xenobiotics by 
inducing xenobiotic-metabolizing enzymes in animals and humans (quoted from 61). 
Increased consumption of these vegetables, for example broccoli, cabbage, cauliflower, 
and Brussel sprouts has been related to a reduced risk of bladder, colon and rectum cancers 
(62) . 
Brussel sprouts may have a protective factor against the AFB 1 carcinogenicity. This 
vegetable significantly decreased AFB 1-DNA binding and increased GST activities in rats. 
lndole-3-carbinol, a compound found in cruciferous vegetables did not have much effect on 
the DNA binding to AFB 1 or the OST activity (61). The same investigators also found 
that the route of administration of AFB 1, intragastric or intraperitoneal, did not change the 
inhibition of AFB 1-DNA binding. Thus, they concluded that the small intestine may not 
play an important role in the AFB1 metabolism. However, in another study that utilized 
trout, 1000 and 2000 ppm of indole-3-carbinol were shown to strongly depress AFB 1-
D NA adducts formation (63). R-Ooitrin, another compound common in cruciferous 
vegetables, also exhibited anticarcinogenic role by inhibiting AFB 1-DNA binding, 
increasing OST activity, and enhancing biliary excretion of AFB 1 in rats ( 64 ). 
2.1 .5.d Plant flavonoids and Phenolic Compounds 
Several derivatives of five major plant flavonoids, namedly, flavone, flavonol, 
isoflavone, and flavonol have been tested on AFB1-DNA binding and activation of AFBt 
(65). Most of the flavonoid derivatives significantly inhibited the adducts formation. 
However, flavonols had the most potent effect on the inhibition of the binding and 
activation of AFB i. Flavonols also showed greater inhibition of AFB 1 mutagenicity in 
bacterial systems ( 66). 
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Phenolic compounds have also been shown to have protective effects on 
mutagenicity caused by AFB 1 . Gallic acid, chlorogenic acid, caffeic acid, dopamine, p­
hydroxybenzoic acid, and salicyclic acid depressed AFB 1-induced mutagenicity in a 
bacterial system containing rat-liver microsomes. The inhibition occurred when the 
compounds and AFB 1 were administered concwrently (67). 
2. 1 .5 ,e Antioxidants 
Antioxidants, such as butylated hydroxyanisole (BHA) and butylated 
hydroxytoluene (BHT), are chemicals commonly added to food to prevent spoilage due to 
oxidation. Rats fed a BHA added diet (7500 ppm) had significantly lower AFB 1-DNA 
binding, higher GST activities, and higher biliary excretion of AFB 1 (64). In trout; 
however, BHA had no effect on liver tumor incidence, AFB 1-DNA binding, and AFB 1 -
gluthathione conjugation (68). These results have led to suggestion that in mammals, an 
increase in the gluthathione conjugation is the basis for BHA inhibition of AFB 1 
carcinogenicity. In in vitro system; however, BHA as well as BHT markedly inhibited 
AFB 1-DNA binding (46). 
2, 1 ,5 ,f Pru is and Other Compounds 
Pretreatment of an anti-seizure drug, phenobarbital, in rats increased AFB 1 
activation in vivo and in vitro (69,70). However, it also induced GST activity and 
enhanced the excretion of biliary AFB 1-gluthathione conjugate; therefore, the overall 
hepatic binding of AFB 1 to DNA is reduced Ethanol pretreatment on the other hand, 
increased the activation of AFB 1 but not the activity of OST. Thus, ethanol pretreatment 
increased binding of AFB 1 to DNA and RNA (7 1 ). 
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Cortisol pretreannent in female rats significantly increase the acute hepatotoxicity 
induced by AFB 1 . This effect of cortisol was dose dependent and supponed by increased 
monality rate, hepatic triglycerides, and binding of AFB 1 to DNA and protein (72). This 
effect was perhaps mediated via increased metabolism of AFB 1 to its epoxide derivative as 
well as hydroxylated derivatives (AFM1 and AFQl) in microsomes since activity of aniline 
hydroxylase was elevated in cortisol pretreated rats. 
2,2 CARNITINE 
2.2, 1 History 
Camitine was first discovered by two Russian scientists from muscle extracts in 
1905 ( quoted from 73). It was named carnis , which is a Latin word for flesh or meat. In 
the 1940's, carnitine was found to be essential for the mealworm by Fraenkel, and was 
named Vitamin Bt . In the late 1950's and early 60's, it was discovered that camitine is 
involved in the transportation of fatty acids into the mitochondria for 6-oxidation (7 4). 
However, not until 1973 did camitine gain much attention and investigation, that is, when 
the first camitine deficient patient was described by Engel and Angelini (75). 
2,2.2 Chemisny and Dietary Sources 
Carnitine is a quarternary amine and is very similar to choline and amino acids. 
However, unlike amino acids, it is not involved in protein synthesis. Chemically, it is 
known as 3-hydroxy-4-N-trimethy !amino butyric acid. It exists in two forms or isomers, 
L-camitine and D-camitine. Only the L-camitine is biologically active. The D-isomer is 
not only inactive, it has been reponed to depress L-camitine utilization (76). Carnitine is 
not essential for humans since it can be produced in the body, and therefore, is not 
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considered a vitamin. Muscle tissue of animals, lamb liver, yeast, and milk are very good 
sources of dietary carnitine. Most vegetables and grains such as cauliflower, cabbage, 
spinach, barley, and rice contain very little or no camitine. More detailed reviews are 
available on carnitine history, biosynthesis, dietary sources and functions (73,76,77). 
2,2.3 Camitine Biosynthesis 
The biosynthesis of carnitine starts from two essential amino acids, lysine and 
methionine, in a five step pathway involving frye �ferent enzymes. Niacin, vitamin B6, 
vitamin C, and iron are also required for biosynthesis of carnitine in animals (quoted from 
77). (Refer to Figure 2.3 for the complete pathway of camitine biosynthesis.) 
In rats, the first 4 steps of the pathway occur in the liver, kidney, skeletal muscle, 
cardiac muscle, testis, and epididymis. However, the final step occurs only in rat liver 
(78). The human brain, liver, kidney, heart, and skeletal muscle can conven N­
trimethyllysine to 4-N-trimethylamino butyric acid; but only the liver, kidney, and brain can 
convert 4-N-trimethylamino butyric acid to camitine (79). This is because the enzyme 
catalyzing the final step, butyrobetaine hydroxylase, is present only in the tissues where 
carnitine is finally synthesized. Therefore, carnitine must be transponed to those tissues 
that do not have the final enzyme. 
2,2,4 Functions of Camitine 
The main function of camitine is the transportation of long-chain fatty acids from the 
cytosol into the mitochondria to allow beta-oxidation to take place. In brief, other functions 
of carnitine include metabolism of branched-chain amino acid, initiation of ketogenesis, 
thermogenesis in brown adipose tissue of inf ant rats, stimulation of gluconeogenesis, 
facilitation of urea removal from blood and tissue, the removal of shon-chain and medium-
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Figure 2.3 The Biosynthesis of Camitine . 
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Source: Leibovitz ( 1984). Camitine: How it functions in your body. In: Camitine: The 
Vitamin BT Phenomena. pp. 24-38, Dell Publishing Co., Inc., New York. 
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chain acyl residues accumulated in the peroxisomes, prevention of fatty liver development, 
and detoxicification of drugs (refer to 73,76,77, 80, and 81 for complete review of the 
above functions). 
2. 3.5 Carnitine and Drue;/Xenobiotic Interactions 
Chronic consumption of ethanol is widely known to inhibit beta-oxidation which 
leads to fatty infiltration in human and animal livers (10, 12). Impaired oxidation and/or 
increased lipogenesis are the suggested mechanisms of this malady (1 2) . In addition, 
ethanol depresses the activity of camitine palmitoyltransferase I, the rate limiting enzyme in 
the transportation of long-chain fatty acids into the mitochondria (82). This inhibition may 
also contribute to accumulation of fat in the liver. Supplementary carnitine has been 
reported to inhibit this fatty liver phenomena caused by ethanol ( 13, 14, 15) .  Carnitine may 
also offer protection against the toxicity of other alcohols such as methanol, isopropanol 
and ethylene glycol (a common anti-freeze.) This is because carnitine prevents 
accumulation of these alcohols by enhancing their excretion in the urine (83). 
Carnitine may also alleviate the toxicity of adriamycin (doxorubicin hydrochloride), a 
widely used anti-cancer drug. Adriamycin treatment has resulted in a series of acute and 
chronic side-effects and cardiomyopathy in rats and humans and (quoted from 16,84). It 
was found that carnitine administration decreased histophatological changes and 
ameliorated irregular heart performance due to adriamycin ( 16,84). Furthermore, carnitine 
lengthened the survival rate of mice following chronic adriamycin administration than the 
mice that were administered with adriamycin only (85). 
V alproic acid, a short chain fatty acid, is a frequently used anticonvulsant drug. This 
drug has produced very serious side effects similar to Reye's syndrome (i.e. stupor, 
hyperammonia, coma, and hepatic dysfunction) (86). Vaproic acid treatment in epileptics 
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lowers the serum free carnitine but increases the short-chain acylcarnitine concentrations in 
the patients (87 ,88). When vaproic acid was treated together with other drug such as 
primodone, phenobarbital, ethosuximide or phenytoin, total camitine was markedly 
reduced. 
Lately, camitine has been found to conjugate with certain drugs/xenobiotics. For 
example, vaproic, cycopropanecarboxylic (CPCA), and pivalic acid have been found to 
conjugate with camitine and are then excreted in the urine by humans (quoted from 89). 
Prolonged high doses of CPCA decrease free and total carnitine in the hearts of female rats. 
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CHAPTER 3 
MATERIALS AND METHODS 
3, 1 ANIMALS AND HOUSING 
Male Sprague-Dawley rats (Harlan, Indianapolis, ID) were used in this experiment. 
They were acclimatized to the animal facility for 7 d upon arrival and had free access to 
food and water. All rats were housed in individual wire-meshed bottom, suspended, 
stainless steel cages in a cubicle of an AAALAC approved animal facility. The room 
temperature was maintained at 23 ± 1 <>c, relative humidity around 45%, and with a 12-h 
light/dark cycle. 
3,2 DIETS 
During the acclimatization period, the animals were fed Purina Rodent Chow pellets 
#5001 (Ralston Purina Co., St Louis, MO). For the experiment, the diets were either 
ground Purina Rodent Chow, or the same ground Purina Rodent Chow supplemented with 
0.5% ( w/w) L-carnitine-HCI (Sigma Chemical Co., St Louis, MO) which contained about 
0.4% L-carnitine. The diets and water were provided ad libitum . 
3,3 EXPERIMENTAL DESIGN AND TREATMENTS 
In Experiment 1 , twenty Sprague-Dawley rats were divided into 4 groups (b.w. 
about 270-273 g) as shown in Table 3. 1. NSC and NSA groups consisted of the non-
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Table 3. 1 Design of Experiment 1 .  
NSC 
# Animals 5 
Body Weight, 27 1 
(g ± SD) ± 1 1 
L-Camitine.HCL 
(%,w/w) 
AFB 1 
(mg/kg b.w.) 
1 NSC = Nonsupplemented Control 
NSA = Nonsupplemented Aflatoxin 
GROUPS l 
NSA csc CSA 
5 5 5 
270 274 273 
± 1 3  ± 9.2 ± 9. 8 
0.5 0.5 
1 .0 1 .0 
CSC = Camitine-supplemented Control 
CSA = Camitine-supplemented Aflatoxin 
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carnitine supplemented rats and CSC and CSA were the carnitine-supplemented animals. 
For Experiment 2, 10 rats were divided into 2 groups (Table 3.2). NSA group was fed 
with the regular diet, while CSA group received the carnitine-supplemented diet. Bcxly 
weights were monitored weekly. 
After 6 weeks on the diet, a single oral dose of 1 mg/kg [3H]AFB 1 (Moravek 
Biochemicals, Brea, CA) was administered by gavage to NSA and CSA groups in 
Experiment 1 and to both groups in Experiment 2. Unlabelled AFB 1 (Sigma Chemical 
Co., St. Louis, MO) was dissolved in methanol while the [3H]AFB 1 came already 
dissolved in methanol. The cold AFB 1 was mixed with [3H]AFB 1 to get the spec. act. of 
8 µCi/µmol. The above AFB 1 solution was dissolved in com oil to give a final 
concentration of 1 .0073 mg of diluted [3H]AFB 1 in 1 ml of corn oil. NSC and CSC 
groups were given 1 ml/kg suspension of methanol:corn oil ( 1 :9, v/v) by gavage. 
Six hours in Experiment 1 and 24 h in Experiment 2 after the [3H]AFB 1 
administration, the animals were anesthetized with mcthoxyflurane (Pitman-Moore, Inc., 
Washington Crossing, NJ) and blood samples were collected by cardiac puncture. The 
animals were euthanized by exsanguination, and the livers and kidneys were removed. The 
livers were rinsed with cold 0.9% NaCl to remove blood, blotted, dipped in liquid 
nitrogen, weighed, and stored immediatedly at -70 oe. The kidneys were also dipped into 
liquid nitrogen, weighed and stored at -70 °c. 
3,4 TISSUE HOMOGENATE PREPARATIONS 
Whole livers and kidneys were allowed to thaw. The livers were added to 1 volume 
of cold 0.2M Tris buffer containing 1 . 15% KCl in a teflon glass homogenizer. The 
kidneys were placed in a teflon glass homogeniz.er containing 2 volumes of the Tris buffer. 
Table 3.2 Design of Experiment 2. 
NSA 
# Animals 5 
Body Weight, 338 
(g ± SD) ± 8  
L-Camitine.HCL 
(%,w/w) 
AFBt 1 .0 
(mg/kg b.w.) 
1 NSA = N onsupplemented Aflatoxin 
CSA =-Carnitine-supplemented Aflatoxin 
GROUPS 1 
CSA 
5 
336 
± 7 
0.5 
1 . 0 
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The tissues were homogenized by 6 complete strokes according to the method of Campbell 
et al. (51). The livers and kidneys were rinsed with I volume of the buffer, vortexed and 
each homogenate was placed into 7 separate 5 ml capacity culture tubes. The tissue 
homogenate were prepared at 0-5 oC and stored at -70 oc. For analysis, only one tube of 
each tissue homogenate was thawed and used for one assay. Thus, repeated thawing and 
freezing were avoided and homogenate samples in different tubes were used for 
determination of the tissue radioactivity, camitines, lipids, macromolecules, and AFB I -
macromolecules adducts. 
3,5 BLOOD PLASMA PREPARATION 
The blood samples collected by cardiac puncture were placed into heparin-containing 
tubes (143 USP units of s�um heparin, Becton-Dickinson, Rutherford, New Jersey). 
They were later centrifuged at 1500 x g at 4 oC for 10 min. The plasma was transferred 
into culture tubes and stored at -70 oC. The plasma was analysed for all the assays as 
carried out in the tissue homogenates except for the quantitation of macromolecules and 
AFB I-macromolecules adducts. 
3,6 ANALYTICAL PROCEDURES 
3.6, 1 Tissue Radioactivity 
The measurement of tissue radiuactivity was done following the method of Petroff et 
al. (90). 100 µg of the tissues (livers or kidneys) was added with 2 ml 2N methanolic 
KOH in scintillation vials. Joe tissues were digested at 70 oC in a water bath for 3 0  min, 
cooled to room temperature, and 15 ml Aquasol-2 (NEN® Research Products, Boston, 
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MA) was added to each tubes. Approximately 300 µl glacial acetic acid was added to 
decrease the random coincidence monitor (RCM) to less than 5%. The radioactivity was 
counted in a liquid scintillation counter (LS-3801Beckman Instrument, Irving, CA.) 
3.6,2 Carnitine 
Tissue and plasma carnitines were detennined according to the radioisotopic method 
of Cederblad and Lindstedt (91) as described by Sachan et al. (13). Three different 
fractions of catnitine were measured, namely, free carnitine or non-esterified carnitine 
(NEC), shon-chain acylcamitine or acid soluble acylcamitine (ASAC), and long chain 
acylcarnitine or acid insoluble acylcarnitine (AIAC). Summation of these three fractions 
gave the total carnitine (TC) of the tissue or plasma samples. 
Perchloric acid was used to extract the ASAC, while potassium hydroxide and 
heating were used to hydolyze and extract AIAC. The NEC was assayed by the addition of 
carnitine acetyltransferase (CAT) and sodium tetrathionate which drove the following 
reaction to the right by binding of CoASH. 
�-Cami tine + [ 1- 14 C]Acetyl CoA CAT > [ 1- 14 C]Acetyl Carnitine + CoASH 
The reaction mixture was passed over an ion-exchange resin column where 1- 14C 
acetyl camitine was eluded and unreacted-labeled acetyl CoA was trapped. Scintillation 
solution was added to the eluate and radioactivity was detennined in a Beckman scintillation 
counter. Tissue carnitine was expressed in µmol/g wet wt of tissue, and plasma carnitine 
as nmol/ml. The details of carnitine determination procedures used in Sachan's laboratory 
(13) are described as follows: 
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3.6.2,a Rea�ents 
1. 0.5 mM camitine standard solution (stock): 9.88 mg L-camitine HCL (Sigma 
Chemical CO., St. Louis, MO) was dissolved in cold glass distilled water (GDW) 
and diluted to 100 ml in a volumetric flask. This stock standard was diluted 1:2 
to give a working standard concentration of 0.25 mM. 
2. 22.9 mM L-palmitoylcarnitine standard (stock): 1.0  ml of GDW was added to a 
vial containing 10ml of L-palmityl carnitine (Sigma Chemical Co., St. Loius, 
MO). This stock standard was diluted 1: 100 to give a working standard 
concentration of 0.229 mM. 
3 .  Camitine standard mixture: Working standard were prepared by mixing equal 
volumes of L-camitine and L-palmitoyl camitine. 
4. 0.5 M Potassium hydroxide: 28.05 g of KOH was dissolved in some GDW and 
diluted to a volume of 1 liter. 
5. 4 M Potassium hydroxide: 56. 11  g of KOH was dissolved in some GDW and 
diluted to a volume of 250 ml. 
6. 0.6 M Perchloric acid (PCA): 5 1.26 ml of 70% PCA was added in some GDW 
and diluted to a volume of 1 liter. 
7. 0. 1 M Sodium tetrathionate: 0.6756 g of anhydrous sodium tetrathionate (J. T. 
Baker Chem. Co., Phillipsburg, NJ) was dissolved in GDW and diluted to a 
volume of 25 ml. 
8. 0. 1 % Phenol red: 100 mg of phenol red (Sigma Chemical Co., St. Laius, MO) 
was dissolved in absolute ethanol and made to a volume of 100ml. Phenol red 
tubes were prepared by adding one drop of phenol red to 12 x 75 mm Pyrex 
glass tubes and allowed to dry. 
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9. [ I- 14C] acetyl Coenzyme A: 50 µCi of [ I- 14C] acetyl Coenzyme A (Amerstam 
Corp., Chicago, IL) was dissolved in cold GDW and made to a volume of 3 00  
ml. 5.0 ml aliquots were dispensed into plastic vials and frozen at -70 oc. 
10. IM Potassium bicarbonate: 1 g potassium bicarbonate (Certified ASC, Fisher 
Scientific Co., Fair Lawn, NJ) was dissolved and made to a volume of 10 ml 
with GDW. Solution was stored at room temperature and made daily. 
11. 0. 1 M acetic anhydride: 0.5 ml of acetic anhydride (Fisher Scientific Co., Fair 
�wn, NJ) was added to 4.95 ml of cold GDW and used immediatedly for acetyl 
CoA solution. 
12. 0. 1 mM acetyl Coenzyme A: 10 mg of acctyl Coenzymc A (Sigma Chemical Co., 
St. Louis, MO) was added to 0.5 ml cold GDW and mixed. Then, 100 µl of 1 M 
potassium bicarbonate was added and mixed, and followed by the addition of 200 
µI of 0. 1 M acetic anhydride. The solution was made up to 80 ml with cold 
GDW, mixed thoroughly, and dispensed into plastic vials and frozen at -70 °C. 
13 .  Carnitine acetyltransferase (CAT): CAT from pigeon breast muscle (Sigma 
Chemical Co., St. Louis, MO) was diluted with GDW to give an enzyme activity 
of. 50 units/ml. 
14. 1 M (3 -(4-morpholino)propanesulfonic acid] MOPS: 20.92 g of MOPS (Sigma · 
Chemical Co., St. Louis, MO) was added to about 80 ml of GDW. The pH was 
adjusted 7.4 with 4 M potassium hydroxide and was diluted to a volume of 100ml 
with GDW. 
15. PCA/MOPS-1: 20.9 g of MOPS was added to 50 ml of 0.6 M PCA and brought 
up to a volume of 100 ml with GDW. The solution was stored at 4 °C. 
16. PCA/MOPS -II: 20.9 g of MOPS was added to 20 ml of 0.6 M PCA and 
brought up to a volume of 100 ml with GDW. The solution was stored at 4 oC. 
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17. 0. 1 M ethylene glycol-bis (beta-amino-ethylether) N, N-tetraacetic (EGTA), pH 7: 
1.902 g EGTA (Sigma Chemical Co. ,  St. Louis, MO) was added in 3 0  ml GDW, 
adjusted to pH 7 .0 with 4 M potassium hydroxide, and diluted to 50 ml with 
GDW. 
18. 0. 1 mM [ 1- 14C] acetyl Coenzyme A solution: 2 : 1 volumes of (l - 14C] acetyl CoA 
and 0. 1 mM acetyl CoA were mixed and stored at 4 oC. 
19. Reagent mixture for one assay: 1 M MOPS, pH 7.4, 120 µl; 0. 1 M EGTA, pH 
7.0, 20 µl; 0. 1 M sodiu� tt:trathionate, 20 µ1; 0. 1 mM [ 1- 14C]-acetyl CoA 
solution, 200 µI; .GOW, 40 µI; to a volume of 400 µI. 
20. 8% bovine serum albumin (BSA): 4 g of BSA (Fatty acid poor, Fraction V, ICN 
Pharmaceuticals Inc. , Life Sci. Group, Cleveland, OH) was dusted into about 20 
ml of GDW, stirred gently, and diluted to 50 ml. 
2 1. Scintillation fluid: Ready-Solv® CP (Beckman Instruments, Palo Alto, CA). 
3,6,2,b Procedure 
Aliqouts of 200 µI of tissue homogenates and blood serum were placed in 200 µI of 
PCA in a 12 x 75 mm Pyrex glass test tubes. The contents were vortexed thoroughly and 
centrifuged (Model TJ-6, Beckman Instruments, Palo Alto, CA) at 1 500 x g for 10 minutes 
at 4 oc. Nonesterified camitine (NEC) and acid soluble acylcamitine (ASAC) were 
contained in the supernatant, while the acid insoluble camitine (AIAC) was contained in the 
pellet. 
Cami tine standards were made by adding 10, 20, 3 0, 40, and 60 µl of carnitine 
standard mixture to 200 µI of PCA in 12 x 75 mm Pyrex glass test tubes (Refer to Table 
3 .3 ). Blank was made by mixing 100 µl of GDW, 100 µI of BSA, and 200 µ of PCA . 
The standards and blank underwent the same procedures as in the samples. 
0.25 mM 0.23 mM 
Carnitine P-Carnitine 1 
-------··-------------------------
(µI) (nm) (µl) 
0 0 0 
5 1 .25 5 
10 2.50 10 
15  3.75 15  
20 5.00 20 
30 7.50 30 
I L-Palmityl Carnitine 
2Glass distilled water 
3Bovine serum albumin 
4 Perchloric acid 
(nm) 
0 
1 . 1 5  
2.30 
3.45 
4.60 
6.90 
Table 3.3 Carnitine Standard Preparations. 
GDw2 8% BSA3 6% PCA4 Total 
(µI) (µI) (µI) (µl) 
100 100 200 400 
90 100 200 400 
80 100 200 400 
70 100 200 400 
60 100 200 400 
40 100 200 400 
Total Camitine 
(nm) 
0 
2.40 
4.80 
7.20 
9.60 
14.40 
w 
.J::. 
150 µI and 100 µI of the supernatant from the tissue samples, blood, blank and 
standards were transferred to 12 x 75 mm phenol red tubes that were labeled NEC and 
ASAC respectively. The pellets were drained of the supernatant by inverting the tubes. 
N onesrerified Camitine Detennination 
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35 µl of 1 M potassium bicarbonate was added to the 150 µI of the supernatant in the 
phenol red test tube and vonexed. The contents were slightly acidic as indicated by a 
golden yellow color. The mixtures were held for 3 0  min on ice. 
Acid Soluble Acylcarnitine Detennination 
75 µI of 0.5 M potassium hydroxide was added to the 100 µl of the supernatant in 
the phenol red test tube and vonexed. The contents were slightly alkaline as indicated by a 
purple-red color which was essential for hydrolysis. The contents were incubat� in a 3 7  
oc rotating water bath (100 shakes/min) for 3 0  min for complete hydrolysis. The mixtures 
were then neutralized by adding 3 0  µl of PCA/MOPS-11, and vonexed. They were held on 
ice for 3 0  min. 
Acid Insoluble Acylcamirine Detenninarion 
The pellet was washed twice with 200 µI of 0.6 M PCA and the washes were 
drained by inverting the tube. One drop of phenol red indicator and 200 µl of 0.5 M 
potassium hydroxide were added to the tube and vonexed vigorously for several min until 
the pellet was completely dissolved. The contents were alkaline indicated by purple-red 
color and were hydrolyzed in a 65 oC shaking water bath ( 100 spm) for 60 min. Then, 
3 6  
1 00  µI of PCA/MOPS-I was added and vortexed to neutralize the contents. They were held 
on ice for 3 0  min. 
3,6.2.c Assay for Camitine 
The NEC, ASAC, and AIAC tubes were centrifuged at 1500 x g at 4 °c for 1 0  min. 
A 100 µI aliqout was transferred from each of the fractions to 1.5 ml microfuge tubes 
separately. Four hundred µI of reagent mixture were added followed by 20 µI of carnitine 
acetyltransferase (CAn. The tubes were capped, mixed by gentled tapping, incubated in a 
37  oC shaking water bath for 3 0  min. Later, 200 µI of the incubated mixture was 
transferred onto a mini column, and the elutant was collected into plastic mini scintillation 
vial (Beckman Instrument, Palo Alto, CA). The mini columns were made by stuffing the 
area above 5-3 /4" Pasteur pipettes (Fisher Scientific Co., Fair Lawn, NJ) with glass wool. 
Anion Exchange Resin, AG I-X8, 200-400 mesh, Cl-form (Bio-Rad Laboratories, 
Richmond, CA) was added up to the 9 cm mark measured from the tip of the pipette. 
When the 100 µl aliqout was fully absorbed, the column was washed with 2 portions of 
500 µI GOW, and the washes were also collected into the same respective scintillation vial. 
Then, 5 ml of scintillation fluid was added to each vial, capped, mixed by swirling, and 
counted for 10 min/vial in a scintillation counter (LS-3 801 Beckman Instruments, Irving, 
CA). 
Dual radioactivity counts were employed to determined the amount and AFB 1 
conjugation to each of the carnitine fractions (refer to Appendix A-3 . 1 for the procedures �f 
dual radioactivity counts as described in the Beckman Liquid Scintillation Systems 
Operating Manual, Beckman Instruments, Irving, CA.) The disintegration per minute 
(DPM) for the NEC, ASAC,and AIAC, and their standards were adjusted by substracting 
the blank's DPM. Standard curves for the camitine fractions were plotted as shown in 
Figure 3. 1 and 3.2. The calculation for camitine concentrations were as follows: 
Liver : DPM I S D F = umoles carnitine X • •  X • .  
g tissues 
Blood serum: DPM x I.S. x D.F. = nmoles carnitine 
where: DPM = Disintergration per min 
I.S .  = Inverse slope 
ml serum 
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D.F. = Dilution factor (appropriate to bring the amount of camitine 
to 1 g or 1 ml) 
3.6.3 Total Lipids 
Total lipids concentrations of the liver, kidn�y, and plasma were determined 
according to the phosphoric acid-vanillin reaction method of Ellenston and Caraway (92). 
The principle of this method is that unsaturated fatty acids are oxidised to form ketones that 
react with phosphovanillin to yield a pink-colored product. 
3,6,3.a Rea�ents 
1 . Sulfuric acid (AR). 
2. Phosphoric acid-vanillin reagent: 1 g of vanillin (Sigma Chemical Co., St. 
Louis, MO) was added to 160 ml of GDW, and brought up to a volume of 500 
ml with phosphoric acid 
3. Stock standard : 1 g of olive oil was placed and mixed in a 100 ml volumetric 
flask containing some chloroform. The volume was brought up to the volume 
with chloroform, mixed thoroughly, and stored at -20 oC. 
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Figure 3.2 Acid Insoluble Acylcarnitine Standard Curve. 
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R = 1 .00 
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4. Working standard: 1 ml of the stock standard was placed in a 10 ml volumetric 
flask, brought up to the mark with chloroform, and stored at -20 °c. 
3,63,b Procedure 
Tissue homogenates ( 1 :8  w/v) and blood serum (0.2 ml) were transferred to 
different 16 x 150 mm glass test tubes, while 0.2 ml GOW was placed for blank. For the 
I 
standards, 0.05, 0. 1 ,  and 0.2 ml of the working standard solution were placed into 
separate tubes. The chloroform in the standards was evaporated off with a stream of 
nitrogen, and 0.2 ml GOW was added and 5 ml concentrated sulfuric acid were added to all 
tubes and vortexed. The tubes were stopped and heated at 100 oC for 10  min in a heating 
block (Precision, GCA Corp.). The tubes were cooled to room temperature. Two hundred 
µl of the contents of each tube was transfered to 12 x 75 mm test tubes and 3.0 ml 
phosphoric acid-vanillin reagent was added and mixed The tubes were allowed to stand 
for 60 min in darkness. Absorbances were read at 520 nm in a Beckman spectrophometer. 
The standard curve is shown in Figure 3.3. The concentrations were calculated as follows: 
Total lipids (mg/g tissue or mg/ml serum) = Abs. x Slope x D.F. 
where; Abs. = Corrected absorbance of sample 
D.F. = Dilution factor 
3.6,4 Tri�lycerides 
Triglyceride contents were measured according to the procedure of Geigel et al. (93). 
The principal of this method is that triglycerides are extracted from the samples by an 
extraction reagent (nonane). Phospholipids or other interfering components are left 
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Figure 3.3 Total Lipids Standard Curve. 
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unextracted. The extracted triglycerides are hydrolyzed by sodium hydroxide and heating. 
The liberated glycerol is then oxidized by sodium periodate to form formaldehyde which 
condenses with ammonia and acetylacetone to foim yellow diacetyldihydrolutict:ic which 
can be measured at 415 nm. 
3.6,4.a Rea�ents 
1 . Extraction reagent: n-nonane/isoproponal (2.0/3.5, v/v). 
2. Triolein standard : 100 mg triolein (Sigma Chemical Co., St. Louis, MO) in 100 
ml extraction reagent ( 1 . 13 mM). 
3. Dilute sulfuric acid, 40 mM. 
4. Transesterifying reagent: sodium hydroxide in isopropanol (1 OOmM/1). 
5. Oxidizing reagent:· sodium periodate (18 mM) in 2 M acetic acid. 
6. Color buffer: ammonium acetate (6.0 M, pH 6.0 at 25 oC). 
7. Working color reagent: 4.0 ml of acetylacetone mixed with 100 ml of the color 
buffer, and let stand for more than 15 min before use. 
3.6,4,b Procedure 
Aliquots of plasma and tissue homogenates (0.2 ml each) were transfered to separate 
16  x 100 mm screw-capped test tubes containing 5.0 ml extraction reagent. Then, 1 .0 ml 
dilute sulfuric acid was added. A blank and standards were made by adding 0, 0. 1 ,  0.2, 
0.4, and 0.6 ml of triolein standard and diluted to 5.0 ml with extraction reagent. All the 
tubes were cennifuged at 1500 x g at 4 °c for 10 min. Later, 0.5 ml aliquot of each upper 
phase was added to 0.5 ml of transesterifying reagent, held at room temperature for 5 min, 
mixed with 0.5 ml of oxidizing reagent, and held again at room temperature for 5 min. 
After the two-phase fraction had developed, 6 ml of the working color reagent was added 
to each tube and incubated at 60 °c for 10 min. The tubes were cooled to room 
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temperature and the absorbance of the standards and samples was read against the blank at 
415  run. See Figure 3.4 for triglycerides standard curve. The calculations were as 
follows: 
where: 
Triglycerides (mg/di) = Abs. x I .S .  ·X D.F. 
Abs. = Absorbance of unknown 
I . S .  = Inverse slope 
D.F. = Dilution factor 
3.6.5 Macromolecules and AfB1-Macromoiecule Adducts Ouantitation 
The extraction and isolation of macromolecules namedly RNA, DNA and protein, 
were done following the procedure of Glazer et al. (94). Perchloric acid (PCA) was used 
to precipitate .the macromolecules. The pellet was treated with potassium acetate, 
chloroform:ethanol, and absolute ethanol to remove lipids. The pellet was resuspended 
with PCA and left overnight. The supernatant contained t!1e RNA fraction. To isolate the 
DNA and protein, PCA was added to the pellet and heated. The supernatant contained the 
DNA fraction. Potassium hydroxide was added to the rest of the pellet and heated to get 
the protein fraction. 
3,6,5,a Reaeents 
1 .  0.2N, 0.5N, I .ON, and 1 .5N PCA from 70% PCA. 
2. 0. 1 N potassium acetate (KAc) in absolute ethanol. 
3. Chloroform:absolute ethanol (l : l ,  v/v). 
4. 1 .0 N potassium hydroxide (KOH). 
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Figure 3.4 Triglycerides Standard Curve. 
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5. 0.04 % indole. 
6. Concentrated HCI. 
7. Chloroform. 
8. Alkaline Copper Sulfate Solution prepared daily by adding 50 ml of O. lN  NaOH 
containing 1 g sodium carbonate, 0.5 ml of 2 % (w/v) sodium-potassium 
tartarate, and 0.5 ml of 1 % (w/v) cupric sulfate. 
9. Phenol Reagent (Sigma Chemical Co., St Louis, MO). 
3.6.5.b Standard Solutions 
The standard solutions were prepared as shown in Table 3.4. Ten ml of calf­
thymus DNA (4.0 mg/ml), yeast RNA (8.0 mg/ml) and bovine serum albumin (BSA) for 
protein (50 mg/ml) were prepared in three different tubes for stock standard solutions. 
Aliquotes of these stock solutions were dispensed into 4 different tubes such that different 
concentrations of the DNA, RNA, and protein were mixed together in one tube for each set 
of working standards. For example, in Standard 1, the tube contained 0.25 mg of DNA, 
0.5 mg of RNA, and 10 mg of protein in a total of 5 ml of working standard solution. 
3.6.5,c Extraction and Isolation 
Aliquotes of 0.4 ml of the 1 : 8  (w/v) liver homogenate (50 mg tissue) and the 
working standard solutions were added to ice-cold I .ON PCA, vortexed, and centrifuged at 
2700 x g for 15 min at 2 oc. For blank, 0.4 ml GDW was added to the blank tube. The 
supernatant was discarded. The pellet was washed and centrifuged 4 times with 1 .5  ml 
0.2N PCA. The supernatant was removed each time. Lipids were removed by treating the 
pellet once with 1 .5 ml of 0. lN KAc in absolute ethanol, twice with 1 .0 ml of 
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Table 3.4 Preparation of Macromolecule Standard Solutions. 
Standard DNA RNA Protein aowl Total Volume 
Tubes # (4 mg/ml) (8 mg/ml) (50 mg/ml) 
----------------µ! (mg)--------------- ml ml 
1 62.5 (0.25) 62.5 (0.5) 200 (10) 4.675 5 
2 125 (0.50) 125 ( 1 .0) 400 (20) 4.350 5 
3 250 ( 1 .00) 250 (2.0) 800 (40) 3.700 5 
4 375 ( 1 .50) 375 (3 .0) 1 600 (80) 2.650 5 
lGiass Distilled Water 
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chlorofonn:absolute ethanol and once with 1 .0 ml of absolute ethanol. During each 
treatment, the tubes were vortexed, centrifuged, and supernatant was drained completely 
(especially the last step). The precipitate was resuspended with 1 .0 ml of 1 .5N PCA, 
vortexed, and left overnight in the refrigerator ( 4 oc for about 1 8  h). The next day, the 
tubes were centrifuged and supernatant was collected The precipitate was washed twice 
with 0.5 ml of 0.5N PCA, vortexed, centtif uged, and the supernatant was collected each 
time. The combined supernatant contained the RNA fraction. The pellet was then added to 
1 .0 ml of 0.5N PCA, vortexed, and incubated in. a .70 oc water bath for 20 min, 
centrifuged, and the supernatant collected This was repeated twice and the combined 
supernatant contained the DNA fraction. The precipitate was dissolved in 1 ml 1 .0N KOH, 
vortexed, and incubated at 70 <>c for 15 min and centrifuged The supernatant contained 
the protein fraction. RNA was determined on the same day, while DNA and protein were 
stored at -70 oC until analyzed 
3.6,5.d Detennination 
RN A was measured spectrophometrically against the blank at 260 nm using UV light 
(94). DNA was determined colorimetrically by the method of Ceriotti (95). One ml of the 
DNA extract was added with 0.5 ml of 0.04% cold indole and 0.5 ml concentrated HCI. 
The tubes were vortexed and heated in a 100 <>c water bath for exactly 10 min. The tubes 
were cooled under running water. The water layer (top layer) was extracted twice with 2 
ml chloroform and centrifuged each time. The lower layer (chloroform layer) was removed 
using a clean Pasteur pipette each time. The samples were read at 490 run against the 
blank. 
Protein determination was carried out as described by Lowry et al. (96). 0.2 ml of 
the KOH protein solution was removed and marked-up to 1 ml with GDW in a 10 ml tube. 
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Six ml of the alkaline copper sulfate solution was added, vortexed, and left to stand for 5 
min at room temperature. Then 0.3 ml of phenol reagent was added, vortexed 
immediately, and left at room temperature for at least 30 min. The tubes were centrifuged 
for 5 min and the absorbance were read at 650 nm against the blank. 
The standard curves were drawn for each of the macromolecules (Figures 3.5,  3.6, 
and 3.7.) The concentrations were calculated as follows: 
DNA/RNA/PROTEIN (mg/g liver) = ABS. x inverse slope x D.F. 
Where, ABS. = Corrected absorbance of sample 
D.F. = Dilution factor 
3.6.5,e r.lHJAFB,1-Macromolecules Adducts 
RNA, DNA, and protein extracts (0.5 ml each) were dispensed into separate 20 ml 
scintillation vials. Fifteen ml of Aquasol-2 was added to the vials and mixed For protein, 
100 µI of glacial acetic acid was added. The radioactivity was counted in a Beckman liquid 
scintillation counter for 10 min. The disintergration per minute (DPM) was calculated as 
follows: 
DPM/mg RNA, DNA, or protein = DPM/0.5 ml sample x D.F. 
Where, D.F. = Dilution factor 
3.7 PRECAUTIONARY AND DECONTAMINATION PROCEDURES 
The safety and decontamination procedures followed during handling of AFB 1 were 
as recommended by Stoloff et al. (97), Fischbach et al. (98), and Castegnaro et al. (99). 
Briefly, when handling the AFB 1 ,  disposable rubber gloves, face mask and lab coat were 
always worn. Dry or concentrated toxins from the manufacturer were handled under the 
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Figure 3.5 DNA Standard Curve. 
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hood. To decontaminate any spillage, 5% sodium hypochlorite (full strength regular 
household bleach} was used to wet or soak the contaminated surf ace for at least 30 sec. 
The surface was then wiped with paper towels. Before washing contaminated laboratory 
wares, they were soaked for at least 30 sec with diluted bleach (0.5% NaOCl}. Refer to 
Appendix A-3.2 for the complete details of the procedures. 
3,8 STATISTICS 
All values are expressed as group mean ± standard error of mean. Two-way crossed 
ANOV A were used when data from 4 experimental groups were analyzed and compared, 
and when significant, Duncan's New Multiple Range Test was used. When analyzing and 
comparing data from 2 experimental groups, Student's t-test was used. The minimal level 
of significance accepted was p S 0.05. 
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CHAPTER 4 
RES ULTS 
The effect of camitine supplemented diet and/or AFB 1 treatment on the rats body 
weight and organ weight are summarized in Tables 4.1 and 4.2. Carnitine supplemention 
had no significant effect on weight gain or liver and kidney weights. AFB 1 treatment too 
had no effect on organ weights. The 24-hour urinary output and amount of AFB 1 excreted 
in the urine were not affected by AFB 1 treatment in both the NSA and CSA groups (Table 
4.3) . Even though it is not significant, the CSA group had slightly larger percentage of 
AFB 1 dose (58.1 1  % ) excreted in the urine than in the NSA group (54. 16% ) .  
The results of the effects of camitine supplemented diet and AFB 1 treatment in 
Experiment 1 are presented in Table 4.4. In the AFB 1 treated rats, the amount of total 
lipids in the liver was significantly lower in the camitine supplemented groups, CSC (59.3 
mg/g) and CSA (59.5 mg/g), compared to the NSA group (65.3 mg/g). The liver 
triglyceride concentrations was lower in the CSC group than the other three groups. 
Carnitine and AFB 1 treatments did not change the amount of total lipid in the kidney . In 
the plasma, the diet x · AFB 1 interaction significantly affected the total lipid and triglyceride 
content indicating that in non-supplemented groups, AFB 1 treatment lowers the 
concentration of the total lipids and triglycerides. In contrast, in the camitine-supplemented 
groups, AFB 1 treatment increased the concentrations of the total lipid and triglyceride in the 
plasma. CSC group had lower amount of total lipids (20% lower) and triglycerides (37 .2 
% lower) content in the plasma than the NSC group. The percent differences in the total 
lipid and triglyceride contents are shown in Appendex A-4. 1. 
Table 4. 1 Effects of Camitine Supplemented Diet on Body, Liver and Kidney Weights 
of Rats in Experiment 1 (6 h Post-AFB1 ). 
Groupsl 
NSC NSA csc 
27 1 .0 ± 5.02 Initial Body Weight (g) 270.4 ± 5.9 273.5 ± 4. 1 
Final Body Weight (g) 395.5 ± 1 3.6 393.0 ± 13.9 398.5 ± 7.4 
Weight Gain (g) 124.5 ± 8.7 122.6 ± 8.6 124.9 ± 4.6 
Liver Weight (g) 1 3.6 ± 0.6 13.2 ± 0.5 12.9 ± 0.3 
Liver/Final Body Weight (%) 3.4 ± 0.09 3.3 ± 0.08 3.2 ± 0.07 
Kidney Weight (g) 2.6 ± 0.09 2.5 ± 0. 13  2.6 ± 0.05 
Kidney/Final Body Weight (%) 0.66 ± 0.0 1 0.63 ± 0.02 0.64 ± 0.01 
CSA 
272.3 + 4.5 
394.3 ± 8.0 
122.0 ± 1 1 .4 
13 .4 ± 0.7 
3.4 ± 0. 1 5  
2.5 ± 0.05 
0.64 ± 0.02 
1 NSC = Nonsupplernented Control; N SA = Nonsupplemented AFB I; CSC = Cami tine S�pplemented; CSA = Carnitine 
S upplernent AFB} .  
2The values are mean ± SEM (n = 5). All values are not statistically different (p � 0.05). 
Ul w 
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Table 4.2 Effects of Carnitine Supplemented Diet on Body, Liver and Kidney Weights of 
Rats in Experiment 2 (24 h Post-AFB 1). 
Initial Body Weight (g) 
Final Body Weight (g) 
Weight Gain (g) 
Liver Weight (g) 
Liver/Final Body Weight (%) 
Kidney Weight (g) 
Kidney/Final Body Weight (%) 
NSA 
338.5 ± 3.72 
403.2 ± 6.3 
64.7 ± 4.0 
1 1 .6 ± 0.3 
2.9 ± 0.05 
2.5 ± 0.06 
0.61 ± 0.0 1 
Groups l 
CSA 
336. 1 ± 3.3 
401 . 8  ± 2.7 
65.7 ± 2.6 
1 2.0 ± 0.2 
3.0 ± 0.06 
2.4 ± 0.05 
0.59 ± 0.01 
lNSA = Nonsupplemented AFB 1;  CSA = Carnitine Supplement AFB 1. 
2The values are mean ± SEM (n = 5). All values are not statistically different (p � 0.05). 
Table 4.3 Effects of Supplementary Camitine on AFB 1 Urinary Excretion in Rats of Experiment 2 (24 h Post-AFB t). 
Groups l 
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NSA CSA % Different 
Amount of Urine 
(ml/24 h) 2 1 .05 ± 4.052a 
Total Amount of [3HJA.FB 1 Excreted 
(µg AFB 1 in 24 h) 223.99 ± 34.85a 
Dose in Urine 
(% ) 54. 16  ± 7.88 
Amount of [3H]AFB 1 Excreted/ml Urine 
(µg AFB1/ml Urine) 1 .40 ± 0. 1 8a 
18 . 10 ± 2.02a 
235 . 17 ± 15 .02a 
58. 1 1 ± 3.74 
1 .56 ± o. 1 sa 
lNSA = Nonsupplemented AFB 1; CSA = Carnitine Supplemented AFB 1 . 
2Toe values are mean ± SEM (n = 4 ). Values with different superscript letter are 
significant (p � 0.05). 
14.0 
5 .0 
7 .3  
1 1 .4 
Liver: 
Total Lipids (mg/g)2 
Triglycerides (mg/g) 
Kidney: 
Total Lipids (mg/g) 
Triglycerides (mg/g) 
Plasma: 
Total Lipids (mg/di) 
Triglycerides ( mg/di} 
Table 4.4 Effects of Diet and AFB 1 on Total Lipid and Triglyceride Contents 
in Rats of Experiment 1 (6 h Post-AFB 1 ). 
Groupsl 
NSC NSA csc 
60.5 ± l .6abx 65.3 ± 2. 1 ax 59.3 + 4. 1bx 
23.5 ± 1 .3ax 27.9 ± o.5ax 24.4 ± 1 .2ay 
28.3 ± 2.2ax 29.9 ± 2.5ax 28. 1 ± 1 . 1 ax 
22.3 ± o.1ax 24.0 ± o.sax 22.3 + 1 .oax 
339. 1 ± 10.3ax 280.5 ± 34_3ax 269 J ± 26.4aX 
82.2 ± 4.4ax 57. 1  ± 4_9ax 5 1 .6 ± 10.1ax 
CSA 
59.5 ± o.5bx 
26. 1 ± o.1axy 
28. 1 + o.5ax 
22.6 ± 1 . 1 ax 
317.5 ± 25.2ax 
76.5 ± 13 .4ax 
1 NSC == Nonsupplemented Control; NSA = Nonsupplemented AFB 1; CSC = Carnitine Supplemented; CSA = Carnitine 
Supplement AFB1 . 
2The values are mean ± SEM (n = 5 for liver and kidney; n = 4 for plasma). Those values in a line bearing the different superscript 
letter (a - c) are statistical ly different (p � 0.05) due to diet treatment, and those bearing different superscript letters (x - z) are 
significantly different (p �0.05) due to AFB 1 by a two-way crossed ANOV A. Diet x AFB 1 interaction was significant only in 
plasma's total lipids and triglycerides (p � 0.05). LIi °' 
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S itnilar results for lipid were observed in Experiment 2 where the animals were 
sacrificed 24 h after the administration of AFB 1 (Table 4.5). Liver total lipid and 
triglyceride contents were statistically lower in the CSA group than in the NSA group. In 
the plasma, the reverse was seen, i.e., NSA group had lower while CSA group had higher 
amount of total lipids and triglycerides. The triglyceride concentration in the CSA group 
was 15 .5% higher than in the NSA group and the difference was highly significant (p S 
0.0 1 ). There were no differences in kidney lipids of the two groups. 
Tables 4.6 to 4. 1 1  show the effects of carnitine and AFB 1 treatments on liver and 
plasma camitine concentrations and the [3H]AFB 1 radioactivities associated with them. 
Camitine supplementation did not significantly affect liver camitine concentrations, 
although all the carnitine fractions were higher in the CSC group as compared to the NSA 
group (Table 4.6). However, AFB 1 treatment increased the NEC contents in both NSA 
and CSA groups when compared to their respective control groups (NSC and CSC). 
Camitine and AFB 1 treatments both elevated ASAC concentrations in the NSA and CSA 
animals as compared to their respective control animals. The amounts of ASAC in the CSA 
rats were significantly higher ( 19 1 .25 nmol/g) than in the NSA rats ( 1 1 5. 33 nmoVg). The 
concentrations of AIAC were not significantly affected by the diet and AFB 1 treannents 
eventhough there was about 50% increase compared to respective controls. The total 
camitine contents were higher in both NSA and CSA groups when compared to their 
control groups. The diet x AFB 1 interactions were not significant in all .the groups to affect 
the concentrations of all the camitine fractions in the liver. 
[3H]AFB 1 radioactivity was only found in the AIAC fraction and is presented in 
Table 4.7 . Though it was not statistically significant, CSA group had 26.2% higher 
amount of AIAC than the NSA groups per g liver. The amount of AFB 1 dose and 
Table 4.5 Effects of Diet and AFB 1 on Total Lipid and Triglyceride 
Contents in Rats of Experiment 2 (24 h Post-AFB 1). 
Groups l 
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NSA CSA % Different 
Liver. 
Total Lipids2 (mg/g) 
Triglycerides (mg/g) 
Kidney: 
Total Lipids (mg/ g) 
Triglycerides (mg/g) 
Plasma: 
Total Lipids (mg/ell) 
Triglycerides (mg/dl) 
59. 8 ± 1 .4a 
21 .7 + 0.5a 
28.8 ± 0.6a 
18 .2 ± 0.4a 
359.5 ± 8.4a 
59.5 ± 3.9a 
55.2 ± o.5b 
19 .0 + 0.4b 
29.0 ± 0.6a 
17.9 + 0.7a 
396. 8 ± 8.2b 
68.7 ± 2.6C 
lNSA = Nonsupplemented AFB 1; CSA = Carnitine Supplemented AFB 1. 
7 .7 
12 .4 
0.7 
1 . 6 
10.4 
1 5. 5  
2Toe v�ues are mean ± SEM (n = 5 ) .  bSignificant at p s; 0.05; CSignificant at p �0.01 .  
Values with same superscript are not significant (p � 0.05). 
Table 4.6 Effects of Diet and AFB 1 on Liver Carnitines (nmoVg) in Rats of Experiment 1 (6 h Post -AFB 1 ). 
Groups l 
Carnitine Fractions --� � � -
NSC NSA csc CSA 
Nonesterified Carnitine 224.73 ± 9 .s32ax 398. 19 ± 33.69ayz 3 19.98 ± 41 .7 1 axz 456.34 + 55.92ay 
(NEC) 
Acid-Soluble Acylcarnitine 45.88 ± 9.55aX 1 1 5.33 ± 11 .07aby 98.04 ± 20.33abxy 191 .25 ± 31 .23CZ 
(ASAC) 
Acid-Insoluble Acylcarnitine 13.46 ± 3.25ax 19. 16 + 2.1oax 15. 10 ± 3.38aX 24. 19 ± 6.01ax 
(AIAC) 
Total Camitine 284.08 ± 1 2.41ax 531.69 + 50.6sabcx 433. 12 ± 59.22acx 67 1 .79 + 9.53bX 
1 NSC = Nonsupplemented Control; NSA = Nonsupplemented AFB I; CSC = Cami tine Supplemented; CSA = Carnitine Supplement 
AFB 1 . 
2Toe values are mean ± SEM (n = 5 ). Those values in a line bearing the different superscript letters a-c are statistically different (p � 0.05) due to diet treatment, and those values in a line bearing a suprscript letters x-z are statistically different (p � 0.05) due to AFB 1 
treatment by a two-way crossed ANOV A. AFB I treatment and AFB I x diet interaction was not significant (p2:: 0.05). 
UI 
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Table 4.7 [3H]AFB 1 Binding to Liver Acid Insoluble Acylcarnitine (AIAC) 
in Rats of Experiment 1 (6 h Post-[3H]AFB 1). 
Groups ! 
NSA CSA % Different 
Amount of AIAC 
(nmol/g liver) 19. 16 ± 2.102a 24. 19 ± 6.01a 
[3H]AFB1 -AIAC adducts/nmol AIAC 
(nmol AFB 1/nmol AIAC) 0.21 ± 0.03a 0.22 ± 0.01a 
[3H]AFB 1 in AIAC/g liver 
(nmol AFB 1/g liver) 3.64 ± 0.21a 3 .89 ± 0.32a 
Amount of dose in AIAC 
(% Dose/pmol AIAC) 16.60 ± 2.94a 17.50 ± 5.77a 
lNSA = Nonsupplemented AFB 1; CSA = Carnitine Supplemented AFB1 . 
2Toe values are mean ± SEM (n = 5 ). Values with different superscript letter are 
significant (p S 0.05). 
26.25 
4.76 
6.87 
5.42 
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Table 4.8 Liver Camitine Contents and [3H]AFB 1-Acid Insoluble Acylcamitine Binding 
in Rats of Experiment 2 (24 h Post-[3H]AFB 1). 
Groups l 
NSA CSA % Different 
N onesterified Cami tine (NEC) 
(nmoVg liver) 438.22 ± 21.032a 608.42 ± 36.63b 38 . 84 
Acid Soluble Acylcamitine (ASAC) 
(nmoVg liver) 261 .90 ± 35 .66a 190.96 ± 26.04a , 27 .09 
Acid Insoluble Acylcamitine (AIAC) 
(nmoVg -liver) 18.79 ± 5.61 a 14.35 ± 3.99a 
Total Camitine 
(nmoVg liver) 749 .46 ± 57.99a 834.53 ± 63. 19a 
[3H]AFB1-AIAC adducts 
(pmol AFB 1/nmol AIAC) 6.47 ± 2.04a 4.82 ± 1 .24a 
. [3H]AFB1 in AIAC/g liver 
(pmol AFB 1/g liver) 84.71 ± 10.45a 101 .22 ± 9 .3oa 
Amount of dose in AIAC 
(% Dose/pmol AIAC) 0.50 ± 0. 14a 0.37 ± o.osa 
lNSA = Nonsupplemented AFB1; CSA = Carnitine Supplemented AFB 1 . 
2Toe values are mean ± SEM (n = 5 ). Values with different superscript letter are 
significant (p � 0.05). 
23 .63 
1 1 . 35 
25.50 
19.49 
26.00 
Table 4.9 Effects of Diet and AFB 1 on Plasma Camitines (µmoVml) in Rats 
of Experiment 1 (6 h Post-AFB 1). 
Camitine Fractions Oroupsl 
NSC NSA csc CSA 
Nonesterified Camitine 51 .02 ± o.472bcd 43.82 ±1 .49d 74.65 + 7.53a 69.98 ± 9.41ac 
(NEC) 
Acid-Soluble Acylcarnitine 1 1 .91 ± 0.33a 10.99 ± 0.5oa 10.72 ± 2.8oa 1 1 .53 ± 2.58a 
(ASAC) 
Acid-Insoluble Acylcamitine 4.47 ± o.35bc 3.56 + 0.22b 6.33 ± o.soa 5.36 ± 0.61ac 
(AIAC) 
Total Camitine 66. 15 ± t .64acd 57 . 80 ± 2.44bd 91 .70 ± 10.78a 90. 80 ± 1 1 .29ac 
2NSC = Nonsupplemented Control; NSA = Nonsupplemented AFB I ;  CSC = Carnitine Supplemented; CSA = Carnitine Supplement 
AFB 1 . 
3Tue values are mean ± SEM (n = 5 ). Those values in a line bearing the different superscript letter are statistically different (p � 0.05) 
due to diet treatment (p � 0.05) by a two-way crossed ANO VA. AFB t treatment and AFB t x diet interaction was not significant (p� 
0.05) .  
°' 
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Table 4. 10 [3H]AFB 1 Binding to Plasma Acid Insoluble Acylcarnitine (AIAC) 
in Rats of Experiment 1 (6 h Post-[3H]AFB 1).  
Groups l 
NSA CSA % Different 
Amount of AIAC 
(µmol/ml plasma) 3.56 ± 0.222a 5.36 ± 0.6 1 b 
[3H]AFB 1-AIAC adducts/µmol AIAC 
(nmol AFB 1/µ.mol AIAC) 79.90 ± 8.20a 57 .00 ± 4. 70b 
[3H]AFB 1 in AIAC/ml Plasma 
(pmol AFB 1/ml plasma) 406.93 ± 43.49a 420.00 ±.26.77a 
Amount of dose with AIAC 
(% Dose/mnol AIAC) 6.33 ± 0.68a 4.50 ± 0.38b 
lNSA = Nonsupplemented AFB 1; CSA = Carnitine Supplemented AFB 1 .  
2The values are mean ± SEM (n = 5 ). Values with different superscript letter are 
significant (p S 0.05). 
50.56 
28.70 
3 .2 1 
28.90 
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Table 4.11 Plasma Carnitine Contents and [3H]AFB 1 -Acid Insoluble Acylcarnitine 
Binding in Rats of Experiment 2 (24 h Post- [3H]AFB1). 
Groups l 
NSA CSA % Different 
Nonesterified Carnitine (NEC) 
(µmol/ml) 39.67 ± 1.232a 
Acid Soluble Acylcamitine (ASAC) 
(µmol/ml) 8.89 ± 1.07a 
Acid Insoluble Acylcamitine (AIAC) 
(µmol/ml) 13.86 ± 2.59a 
Total Camitine 
(µmol/ml) 62.42 ± 2.64a 
[3H]AFB 1-AIAC adducts 
(pmol AFB1/µmol AIAC) 15.02 ± 2.58a 
[3H]AFB 1 in AIAC/ml plasma 
(pmol AFB 1/ ml plasma) 18 1 .98 ± 3.4oa 
Amount of dose with AIAC 
(% Dose/runol AIAC) 1 .16 ± 0.20a 
60.17± 2.s1b 
8.42 ± 0.92a 
17.90 ± 5.46a 
86.48 ± 3.0 1 b 
17.20 ± 5.ssa 
199.74 ± 18.51 a 
1.17 ± 0.46 a 
lNSA = Nonsupplemented AFB1; CSA = Carnitine Supplemented AFB 1. 
2The values are mean ±  SEM (n = 5 ). Values with different superscript letter are 
significant (p � 0.05). 
5 1 . 68 
5 . 29 
30 .85 
38 .54  
5. 8 1  
9 .76 
0.86 
[3H]AFB 1-AIAC adducts were also not significantly affected by carnitine 
supplementation. 
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The amount of NEC in the liver 24 h after the dose of AFB 1 was 38.8% (p S 0.05) 
higher in the CSA group as compared to th� NSA group (Table 4.8). The ASAC, AIAC, 
and total carnitine were not statistically different between the NSA and CSA groups. The 
binding of AFB 1 and amount of dose in AIAC in both groups were also not significantly 
different. 
Camitine treatment had significant effect on plasma carnitine concentrations in 
Experiment 1, but AFB 1 treatment did not (Table 4.9). Camitinc supplementation 
increased NEC concentrations in the CSC group (74.65 µmol/ml) when compared to the 
NSC group (5 1 .02 µmoVml). The ASAC fraction was not affected by carnitine 
supplementation or the AFB 1 dose. The AIAC fraction was higher in the CSC rats than in 
the NSC rats, as well as in the CSA rats when compared with NSA rats. As observed in 
the liver, the AFB 1 was only bound to the AIAC fraction (Table 4. 10). The amount of 
[3H]AFB 1-AIAC adducts and the amount of dose in AJAC were significantly higher in the 
NSA group than in the CSA group. However, since the content of AIAC in the CSA 
group was higher than in the NSA group, the amount of [3H]AFB t/ml of plasma was not 
different between the two groups. 
Plasma NEC and total camitine concentrations were significantly higher in the CSA 
group than in the NSA group 24 h after the [3H]AFB 1 administration (Table 4. 1 1 ). There 
was no difference in the amounts of ASAC, NEC and [3H]AFB 1 -AIAC adduct, and the 
percentage of dose AIAC. 
Table 4. 12 summarizes the [3H]AFB1 concentrations in the liver, kidney and plasma 
of rats 6 h after the dose cf [3H]AFB 1 .  The amounts of [3H]AFB 1 found in the liver, 
kidney, and plasma were not significantly different. Although the CSA group had 14.7% 
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Table 4. 12 Tissue and Plasma [3H]AFB 1 Concentrations 
in Rats of Experiment 1 (6 h Post-[3H]AFB 1). 
Groups l 
NSA CSA % Different 
Liver. 
DPM (l0-4)/g 6.77 ± 0.5 12a 5.77 ± o.soa 14.7 
nmole of AFB 1/g 3.8 1 ± o.2sa 3.25 ± o.2sa 
Kidney: 
DPM (l0-4)/g 1 .2 1  ± 0. 14a 1 . 1 8  ± 0. 13a 2 .5 
nmole of AFB 1/g 0.68 ± o.osa 0.66 ± 0.01a 
Plasma: 
DPM (l0-4)/mI 4.38 ± 0.25a 5.5 1 ± 0.73a 25 . 8  
nmole of AFB 1/ml 2.47 ± 0. 14a 3. 10 ± 0.4 1 a 
lNSA = Nonsupplemented AFB 1; CSA = Carnitine Supplemented AFB 1 . 
2Toe values are mean ± SEM (n = 5 ). Values with different superscript letter are significant 
(p� 0.05). 
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less nmol of AFB1 in the liver and 25.8% more [3H]AFB1 in the plasma than the NSA 
group, the amounts were not statistically significant due to large standard deviation in the 
results. The concentrations of [3H]AFB 1 in the liver and kidney 24 h after the dose of 
[3H]AFB1 were also not affected by the diet treatment (Table 4. 13) .  Howe·ver, CSA 
plasma had 19.8% (p S 0.05) more [3H]AFB1 in the plasma than the plasma of the NSA 
group. 
The effects of carnitine on hepatic macromolecules 6 h after the dose of the AFB 1 are 
shown in Table 4. 14 and 4. 15. Camitine had no effect on the RNA, DNA, and protein 
content in all four groups Qf animal�. However, AFB 1 treatment significantly decreased 
t!le liver RNA content in the NSA group as compared to NSC group, but RNA content in 
the CSC and CSA groups remained relatively unchanged DNA and protein concentrations 
were not affected by the AFB 1 treatment. The interaction of diet x AFB 1 was not 
significant in affecting the macromolecule contents. Although the CSA group had 33.6% 
less AFB 1-RNA adducts than NSA group, the difference was not significant (p  S 0.06) 
(Table 4. 15) . In addition, diet treatment had no effect on the AFB1-protein adduct 
concentrations. However, camitine supplemention markedly decreased (p S 0.0 1 ) the 
amount of AFB 1-DNA adducts in rat livers as compared to nonsupplemented rats . 
The effects of carnitine on the amount of hepatic macromolecules and AFB 1 -
macromolecules adducts 24 h after the dose of [3H]AFB1 are shown in Table 4 . 16 .  
Carnitine supplemented animals had higher amount of RNA, DNA and protein than the 
NSA group. The quantities of AFB 1 binding to all three of the macromolecules were 
significantly reduced in the camitine supplemented group. 
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Table 4. 13  Tissue and Plasma [3H]AFB 1 Concentrations 
in Rats of Experiment 2 (24 h Post-[3H]AFB 1). 
Groups l 
NSA CSA % Different 
Liver: 
DPM (l0-4)/g 3.74 ± 0.352a 3.55 ± 0.22a 5 . 1  
nmole of AFB 1/g 2. f l ± 0.20a 2.00 ± 0. 12a 
Kidney: 
DPM (1�3)/g 9.95 ± 0.6 1a  9.58 ± 0.22a 3 .7 
nmole of AFB 1/g 0.56 ± o.o3a 0.54 ± 0.01a 
Plasma: 
DPM ( l0-4)/mI 4.20 ± 0. 14a 5.03 ± 0.34b 1 9. 8  
nmole of AFB 1/ml 2.37 ± o.osa 2.83 ± 0. 19b 
lNSA = Nonsupplemented AFB1; CSA = Camitine Supplemented AFB 1. 
2Toe values are mean ± SEM (n = 5 ). Values with different superscript letter are 
significant (p;;? 0.05). 
RNA (mg/g) 
DNA (mg/g) 
Protein (mg/g) 
Table 4.14 Effects of Diet and AFB 1 on Hepatic Macromolecule Contents in Rats of Experiment 1 (6 h Post-AFB1 ). 
Groupsl 
NSC NSA csc 
2.08 ± o.022ax 1 .8 1  ± o.09ay 2.02 + 0.06axy 
2.90 ± o.14ax 2.63 ± 0. 16aX 2. 93 ± o.24ax 
140. 9 ± 2.8sax 1 38.1 ± 5.48ax 142.3 ± 4.11ax 
CSA 
1.90 + o.osaxy 
2 .78 ± o.21ax 
1 35.9 + 2.69aX 
1 NSC = Nonsupplemented Control; NSA = Nonsupplemented AFB t ;  CSC = Carnitine Supplemented; CSA = Camitine 
Supplement AFB}. 
2Toe values are mean ± SEM (n = 5). Those values in a line bearing the different superscript letter (a - c) are statistically different (p � 
0.05) due to diet treatment, and those bearing different superscript letters (x - z) are significantly different (p g),05) due to AFB 1 by a two-way crossed ANOV A. Diet x AFB 1 interaction was not significant (p � 0.05) in all cases. 
°' 
\0 
Table 4.15 Effects of Camitine Supplemented Diet on Binding of AFB 1 to Liver 
Macromolecules in Rats of Experiment 1 ( 6 h Post-AFB 1 ). 
Groups l 
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NSA CSA % Different 
RNA 
DNA 
Protein 
(ng AFB 1/mg macromolecules) 
67 .34 ± s.ss2a 
21.08 ± 0.98a 
3.57 ± o.2sa 
44.73 ± 9.03a 
14.84 ± 1.54b 
3.57 ± 0.44a 
lNSA = Nonsupplemented AFB1; CSA = Carnitine Supplemented AFB1. 
33.6 
29.6 
0 
2Toe values are mean ± SEM (n = 5 ). Values with different superscript letter are 
significant (p S 0.01). 
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Table 4. 16 Effects of Camitine Supplemented Diet on Amount of Liver Macromolecules 
and AFB 1 -Macromolecules Binding in Rats of Experiment 2 (24 h Post-AFB 1 ). 
Groups l 
NSA CSA % Different 
RNA 
mg RNA/g liver 2. 8 1 ± 0.012a 2.99 ± O.Q6b 
ng AFB1/mg RNA 65 .96 ± 4.96a 53.95 ± 2.26b 
DNA 
mg DNA/g liver 2.47 ± 0.01a 2.16 ± o.o6b 
ng AFB1/mg DNA 22.29 ± 2.58a 16.26 ± 1 .36b 
Protein 
mg protein/g liver 148.03 ± 4.3 1a 1 8 1 . 1 s ± 1s . 1 3b 
ng AFB 1/mg protein 3.29 ± 0. 15a 3.04 ± 0. 1 3b 
1 NSA = Nonsupplemented AFB 1 ; CSA = Cami tine Supplemented AFB 1 .  
2The values are mean ± SEM (n = 5 ) .  Values with different superscript letter are 
significant (p S 0.05). 
6 .4 
1 8 .2 
1 1 .7 
27 .0 
22 .4 
7 .6  
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CHAPTER 5 
DISCUSSION 
5. 1 CARNITINE AND AFB1-INDUCED FATTY LIVER 
One of the objectives of this study was to examine the effect of carnitine supplement 
on AFB 1-induced changes in the hepatic and plasma lipids. Cami tine supplement 
significantly reversed changes in lipid contents of the liver and plasma which are typically 
induced by AFB 1. Supplementary carnitine significantly inhibited AFB 1-induced increase 
in hepatic total lipid and triglycerides contents. This effect of camitine supports preliminary 
observations (Sachan et al., unpublished) and was analogous to the amelioration of 
ethanol-induced fatty liver (13,14,15) and fatty liver caused by lysine deficiency ( 101) 
funher supporting the lipotropic actions of supplementary camitine. A diet low in 
lipotropes (i.e. marginally deficient in choline and methionine, and lacking in folacin) has 
been shown to cause a significant increase in the lipid content of rat liver (52). In poultry, 
however, choline, inositol, vitamin E and B 12 supplementation of an adequate basal diet 
did not significantly alter the fatty liver caused by aflatoxins (40). 
Aflatoxin-induced decrease in plasma total lipid as well as triglyceride concentrations 
(Table 4.4 and 4.5) is consistent with the studies reponed elsewhere (39 ,41 ). It has been 
suggested that the lipid transport from the blood and peripheral tissues is impaired by 
AFB 1 . Camitine appears to restore the transport system since CSA animals had 
significantly higher lipid levels in the plasma and lower lipid levels in the liver. This 
explanation is in accord with the proposed role of carnitine in inter-organ transport of fatty 
acids and their metabolites (102). Protection of liver from fat accumulation caused by 
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AFB 1 may also be aided by increased B-oxidation fo fatty acids caused by camitine. Actual 
increase in plasma AIAC of the CSA rats (Table 4.9 and 4. 1 9  supports the argument that 
exogenous camitine facilitated exit of fatty acids from the liver. Plasma acylcarnitine were 
also increased in carnitine supplemented alcoholic rats where exogenous camitine 
ameliorated hepatic steatosis ( 13). The increased excretion of medium-chain dicarboxy lie 
acids in the urine of infants fed carnitine deficient formula (103) as well dicarboxylic 
aciduria in infant fed carnitine-free formula ( 104) further lend support to camitine mediated 
exit of fatty acid hypothesis. 
5,2 CARNITINE AND AFB1-MACROMOLECULE 
ADDUCTS FORMATION 
In order to address the second objective of this study, examinations of AFB 1-
macromolecule adducts were carried out The data strongly indicate that supplementary 
camitine minimized binding of AFB 1 to liver RNA, DNA, and proteins (Table 4. 15 and 
4. 16). This AFB 1-DNA adduct was statistically lowered 6 h as  well as 24 h post AFB 1 
administration. Decrease in AFB1-DNA adduct suggest sthat camitine may modulate 
caminogenic action of AFBl since AFB1-DNA adducts have been typically attributed to 
cause carcinogenic response in animals (6,23,24,32,33) and humans (1 ,2,29,32). 
A 30% reduction in AFB 1-DNA adduct formation due to camitine (Table 4. 15) is 
comparable to 9-30% reduction by in vitro addition of riboflavin (46), far better than 9% 
reduction by 60% food restriction (60), and 1 8% reduction by marginal deficiency of a 
mixture of lipotropes (52). Choline deficiency increases (41 %) AFB 1-DNA adduct 
formation ( 105) which may be related to carnitine since choline deficiency also causes 
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camitine deficiency ( 106). Cruciferous vegetables like Brussel sprouts ( 6 1) and chemical 
compounds in them such as R-goitrin (64) have been shown to reduce AFB1-DNA adduct 
50% and 43%, respectively. Food additives like BHA also reduced AFB 1-DNA adduct by 
85% (64). Since many of these studies were done not under conditions identical to 
camitine study, a direct comparison cannot be made. 
Various mechanisms of action of different nutrients and food additives have been 
proposed in conjunction with reported studies (52,6 1 ,63,64, 105, 106). Possible 
mechanisms for interaction of camitine and AFB1 may be proposed as follows: 1) 
carnitine enhances excretion of AFB 1;  2) carnitine retards AFB 1 metabolism; 3) carnitine 
decreases half-life of AFB 1 binding to albumin; and/or 4) carnitine protects cell 
membranes. 
5.3 CARNITINE AND AFBl INTERACTION 
It was hypothesized that camiti.ne by virtue of having an electrophilic nitrogen center 
and a nucleophilic oxygen at pH 7 .4 may may attract AFB 1 and/or its metabolites. AFB 1 
was not associated with NEC or ASAC, but AIAC had significant AFB 1 radioactivity 
associated with it (Table 4. 7 and 4.8). However, increases in AFB 1-AIAC complex in 
CSA animals were not significant. These different may have become significant if one of 
the group was fed a camitine deficient diet. It has been reported that AFB 1-albumin was 
strengthened in the presence of long-chain fatty acids, namely palmitic, stearic, and oleic 
acids, at the concentration range of 0.5 to 2 moles per mole albumin (57). Carnitine has 
been found to conjugate with acidic xenobiotics, which are then excreted in the urine 
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(89,107). Carnitine supplementation, as observed in this study, had no significant effect 
on the amounts of AFB 1  binding to AIAC. 
Carnitine supplementation increased the concentrations of all liver carnitine fractions 
and total carnitine as compared to the nonsupplemented animals, but the increases were not 
statistically significant (Table 4.6). However, in the plasma, carnitine supplementation 
markedly increased the NEC and total carnitine (Table 4.9). These data lead to the 
suggestion that the liver wil l  talce only a certain amount of the exogenous camitine and the 
rest of it is goes to the blood and is transported to peripheral tissues or excreted in the 
urine. It has been reported that the excretion of camitine in the urine was higher when the 
animals were fed with camitine supplemented diet ( 100). 
AFB 1 treatment increased the concentrations of NEC, ASAC and total camitine in 
the liver, but had no effect in the plasma. In another words, AFB 1 causes the liver either tp 
synthesize more camitine or get the camitine from extrahepatic tissues and/or exogenous 
sources. Since camitine supplemented animals had an extra camitine pool in the blood, the 
liver may take up this camitine to accomodate the effect of AFB 1 . The NSA group may 
have to get camitine supply from the blood. As a result, although the CSA group had 
lower plasma camitine than the CSC group, CSA camitine concentrations were still higher 
than the NSC and NSA groups (Table 4.9). The higher concentrations of camitine in the 
liver may explain the reason for the lower amounts of total lipid and triglyceride in the CSA 
· group as compared to the NSA group. Similar observations were found when the rats 
were fed with a liquid ethanol diet and carnitine (14). 
5.4 CARNITINE AND AFB1 CONCENTRATION IN TISSUES AND PLASMA 
Six hours �ter AFB 1 dosing, the amounts of AFB 1 in the liver, kidney, and plasma 
were not statistically different in supplemented or non-supplemented animals. At 24 h after 
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AFB 1 administration, AFB 1 concentrations were significantly lower in the plasma of the 
CSA group than in the NSA group, but AFBt concentrations in the liver and kidney were 
not significantly different. Modification of the method, especially in the digestion and 
decolorization of the tissues, may reduce the deviation among the samples and produce 
more conclusive results. 
5,5 CARNITINE, BODY AND ORGANS WEIGHT AND AFB 1 URINARY OUTPUT 
This study found no significant changes in the body and organ weights in the rats 
fed diet with or without supplementary camitine. These findings are similar to the study 
. ' 
done by Berger (100) who fed various levels of carnitine to Sprague-Dawley rats for 10 d. 
As for the AFB 1 treatment, obviously 6 h or 24 h after a single dose ( 1 mg/kg) of AFB 1 
would not have much affect on the body or organ weights. 
The 24-h total urinary output and the concentrations of AFB 1 found in the urine 
were not significantly different in the NSA and CSA groups. It is important to point out 
that in this urinary study, the sample size was small (n = 4) due to limited number of 
metabolic cages. Fmthermore, there was too much deviation in the amount of urinary 
output in the same group of animals ( e.g., one of the rats in the NSA group excreted nearly 
twice as much urine as rest of the rats in its group, and one of the rats in CSA group 
excreted only 1/3 the amount of urine than the other 3 rats in its· group.) Therefore, limited 
interpretations could be made about these results. However, in a different type of study, 
carnitine supplementation was found to increase urinary volume in rats treated with 
methanoi and isopropanol but not with ethylene glycol (83). The excretion of methanol and 
isopropanol was significantly increased by carnitine supplementation. In a food restriction 
study, the investigators observed that the 9 h urinary excretion of AFB 1 ( as % of dose) 
was significantly higher in the food restricted than the ad lib. animals (60). 
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CHAPTER 6 
SUMMARY AND RECOMMENDATIONS 
6.1 SUMMARY 
The effects of camitine supplementation on AFB I-induced fatty liver and AFB I -
macromolecule adducts formation and effects of AFB I on camitine status were studied in 
male Sprague-Dawley rats. Supplementary camitine reduced AFB 1 covalent binding to 
hepatic macromolecules, namely RNA, DNA and protein. Furthermore, camitine 
prevented the reduction of RNA, DNA and protein concentrations caused by AFB 1 . 
Camitine supplement decreased the total lipid and triglyceride concentrations in the liver 
caused by AFB 1. In the plasma, supplementary camitine restored AFB 1-induced decline 
in total lipid and triglyceride concentrations. AFB 1 treatment of rats 6 h prior to sacrifice 
was observed to cause significant increase in the liver NEC, ASAC, and total carnitine. 
AFB 1 was found to conjugate with AIAC fraction, but not to NEC or the ASAC fractions.  
The conjugation, however, was not significantly affected by supplemented carnitine. The 
concentrations of AFB 1 determined in the liver, kidney and plasma were also not 
statistically different in the camitine supplemented and nonsupplemented rats. Urinary 
excretion of AFB 1 was not affected by camitine supplement. In conclusion, 
supplementary camitine offered protection against AFB 1-induced fatty liver and AFB 1 -
macromolecules adduct fonnation. Further studies may reveal anticarcinogenic potential of 
carnitine. 
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6,2 RECOMMENDATIONS 
The following are some of the recommendations or areas for future studies :  
1 .  The design of the study should include on� group of animals that will be fed with 
camitine deficient diet. Such a study would be expected to maximize effects of camitine in 
cases of aflatoxin toxicity. 
2. Determine the effects of AFB 1 on other major lipid fractions such as cholesterol, 
phospholipids and free fatty acids which may reveal specific lipid fraction(s) affected by 
camitine-AFB 1 treatment 
3.  Measure the influence of AFB 1 on the urinary excretion of camitine and 
determine if the AFB 1 in the urine is conjugated with carnitine. 
4. Determine the effects of carnitine on AFB 1 metabolism and 1\1FO enzymes 
activities. These findings may provide the mechanism on how camitine inhibits the AFB 1-
macromolecule adducts formation. 
5. The number of animals should be increased to get more consistent data. 
80 
LITERATURE CITED 
81 
LITERATURE CITED 
1. Alpert, M.E., Hunt, M.S., Wogan, G.N., & Davidson, C.S. ( 197 1) Association 
between aflatoxin content of food and hepatoma frequency in Uganda. Cancer 28: 
253-260. 
2. Stark, A.A. Molecular aspects of aflatoxin B 1 mutagenesis and carcinogenesis ( 1986) 
In: Mycotoxins and Phycotoxins (Steyn, P.S .  & Vleggaar, R., eds.), pp. 435-445, 
Elsevier Science Publisher, Amsterdam. 
3. Krishnamachari, K.A., Ramesh, V., Nagarajan, V., & Tilak, T.B. ( 1975) 
Investigations into an outbreak of hepatitis in parts of Western India. Indian J. 
Med. Res. 63: 1036- 1044 .. 
4. Francis, J., & Albela, G. Aflatoxin caused /oh sheefun deaths. June 9, 1989. New 
Straits Times (Malaysia). p. 1 .  
5 .  O'Brien, K. Moss, E., Judah, D., & Neal, G ( 1983) Metabolic basis of the species 
difference to aflatoxin B 1 induced hepatotoxicity. Biochem.Biophy. Res. 
Commun. 1 14: 8 1 3-821 .  
6. Adamson, R.H., Correa, P., Seiber, S.M., McIntire, K. , & Dalgard, D .  W .  ( 1976) 
Carcinogenicity of aflatoxin B 1 in Rhesus monkeys : two additional cases of 
primary liver cancer. J. Nat. Canc�r. Inst. 57: 67-68. 
7. Bassir, 0., & Adekunle, A. ( 1970) Teratogenic action of aflatoxin B 1 , palmotoxin Bo 
and palmotoxin Go on the chick embryo. J. Pathol. 102:49-5 1 .  
8 .  Thaxton, J.P., Tung, H.T., & Hamilton, P.B. ( 1974) lmmunosuppression in chicken 
by aflatoxin. Poult. Sci. 53: 721 -725. 
9. Palmgren, M.S. & Ciegler, A. (1983) Aflatoxins. In: Handbook of Natural Toxins, 
Vol. 1 :  Plant and Fungal Toxins (Keeler, R.F. , & Tu, A.T. (eds.), pp. 299-323, 
Marcel Dekker Inc., New York. 
10. DeCarli, L.M., & Lieber, C.S. ( 1967) Fatty liver in the rat after prolonged intake of 
ethanol with a nutritionally adequate new liquid diet. J. Nutr. 9 1 :  33 1-337. 
1 1 . Lebach, W.K. ( 1975) Cirrhosis in the alcoholic and its relation to the volume alcohol 
abuse. Ann. N.Y. Acad. Sci. 252 :  88-94. 
12. Lieber, C.S. ,  Baraona, E, Leo, M.A., & Garro, A. (1987) Metabolism and 
metabolic effects of ethanol, including interaction with drugs, carcinogens and 
nutrition. Mutat. Res. 1 86: 201-233. 
82 
13. Sachan, D.S. ,  Rhew, T.H., & Ruark, R.A. ( 1984) Ameliorating effect of carnitine and its precursors on alcohol-induced fatty liver. Am .J .Clin. Nutt. 39: 738-744. 
14. Sachan, D.S. ,  & Rhew T.H. (1983) Lipotropic effect of carnitine on alcohol-induced 
hepatic steatosis. N utr. Rcpt Intl. 27: 122 1 - 1226. 
15. Rhew, T.H. ( 1984) Effects of carnitinc on ethanol-induced hepatic steatosis. Ph.D. 
Dissertation, The University of Tennessee, Knoxville. 
16. Mcfalls, E.O. , Paulson, D.J., Gilbert, E.F. , & Shug, A.L. ( 1986) Camitine 
protection against adriamycin-induced cardiomyopathy in rats. Life Sciences 38 : 
497-505 . 
17. Quistad, G.B., Staiger, L.E. , & Schooley, D.A. ( 1986) The role of camitine in the 
conjugation of acidic xenobiotics. Drug Met. Disposition 14: 52 1-525 . 
1 8. Park, D.L. & Pohland, A.E. ( 1986) A rationale for the control of aflatoxin in animal 
feeds. In: Mycotoxins and Phycotoxins. A Collection of Invited Papers Presented 
at the Sixth International IUPAC Symposium on Mycotoxins and Phycotoxins, 
Pretoria, Republic of South Africa, July 22-25, 1985 (Steyn, P.S. & V1.!ggaar, R., 
eds.), pp. 473-482, Elsevier Science Publishers, Amsterdam, Netherlands. 
19. Jelinek, C.F., Pohland, A.E. & Wood, G.E. ( 1989) Review of mycotoxin 
contamination. Worldwide occurence of mycotoxins in foods and feeds--An 
update. J. Assoc. Off. Anal. Chem. 72: 223-230. 
20. Heathcoth, J.G. & Hilbert, J.R. (1978) The discovery of aflatoxins . In: Aflatoxins: 
Chemical and Biological Aspects, pp. 1- 14, Elsevier Scientific Publishing Co., Amsterdam, Netherlands. 
2 1 .  Sargeant, K. , Sheridan, A., O'Kelly, J., & Camaghan, R.B. ( 1961 )  Toxicity 
associated with certain samples of groundnuts. Nature 192: 1096- 1097. 
22. Hsieh, D.P.H. & Wong, J.J. (1982). Metabolism and toxicity of aflatoxins. In : 
Biological Reactive lntennediates-IIB. Chemical Mechanisms and Biological Effects, Part B. Advances in Experimental Medicine and Biology (Snyder, R., 
Parke, D.V., Kocsis, J.J. , Jollow, D.J., Gibson, C.G., & Witmer, C.M. , eds.), 
vol. 1 36B, pp. 847-863, Plenum Press, New York 
23. Wogan, G.N., Edwards, G.S., & Newbeme, P.M. 197 1 .  Structure-activity 
relationships in toxicity and carcinogenicity of aflatoxins and analogs. Cancer Res. 
3 1 :  1936- 1942. 
24. Shoenhard, G.L., Hendricks, J.D. ,  Nixon, J.E., Lee, D.J., Wales, J.H., Sinnhuber, 
R.O. & Pawlowski, N.E. (1981 )  Aflatoxicol-induced hepatocellular carcinoma in 
Rainbow Trout and the synergistic effects of cyclopropenoid fatty acids. Cancer 
Res. 41 : 101 1 - 1041 .  
25. Buchi, G . ,  Muller, P.M., Roebuck, B.D., & Wogan, G.N. ( 1973) Synthesis and 
toxicity evaluation of aflatoxin. Life Sci. 13: 1 143- 1 149. 
83 
26. Masri, M.S. , Haddon, W.F., Lundin, R.E. & Hsieh, D.P.H. (1974) Aflatoxin Q1. 
A newly identified major metabolite of aflatoxin B 1 in monkey liver. J. Agric . 
• Food Chem. 22: 5 14-525. 
27. Busby, W.R. & Wogan, G.N. (1979) Mycotoxins and alimentary mycotoxicosis. 
In: Foodborne Infections and Intoxications (Riemann, H. & Bryan, F.L., eds.), 
pp. 5 19-610, Academic Press, New York. 
28. Lin, J., Miller, J.A. & Miller, E.C. (1977) 2,3-Dihydro-2-(guan-7-yl)-3-hydroxy­
aflatoxin Bl , a major acid hydolysis product of aflatoxin B1-DNA or ribosomal 
RNA adducts formed in hepatic microsome-mediated reactions and in rat liver in 
vivo. Cancer Res. 37: 4430-4438. 
29. Groopman, J.D. , Cain, L.G. & Kensler, T.W. (1988) Aflatoxin exposure in human 
populations: Measurements and relationship to cancer. CRC Critical Reviews in 
Toxicology 19: 113- 145. 
30. Wong, J.J. & Hsieh, D.H. (1976) Mutagenicity of aflatoxins related to their 
metabolism and carcinogenic potential. Proc. Natl. Acad. Sci. USA 73 : 2241-
2244. 
3 1. Merkow, L.P., Epstein, S.M. ,  Slifkin, M. & Pardo, M. (1973) The ultrastructure of 
renal neoplasms induced by aflatoxin B 1. Cancer Res. 33 : 1608- 1614. 
32. Bechtel, D.H. (1989) Molecular Dosimetry of hepatic Aflatoxin B 1 -DNA Adducts: Linear correlation with hepatic cancer risk. Regulatory Toxicol. Pharmacol 1 0: 7 4-
8 1. 
33. Thabrew, M.I. & Bababumi, E.A. (1980) Levels of microsomal drug-metabolizing 
enzymes in animals which are susceptible to aflatoxin carcinogenicity: a case of t�e 
duck. Cancer Lett. 9:333-338. 
34. Newberne, P.M. & Butler, W.H. (1969) Acute and chronic effects of aflatoxin on 
liver of domestic and laboratory animals. Cancer Res. 29: 236-250. 
35. Wong, Z.A. & Hsieh, D.P.H. (1980) The comparative metabolism and 
toxicokinetics of aflatoxin B 1 in the monkey, rat and mouse. Toxicol. Appl. 
Pharmacol. 55: 1 15- 125. 
36. Ueno, I., Friedman, L., Stone, C.L. (1980) Species differenc� in the binding of 
aflatoxin BI to hepatic macromolecules. Toxicol. Appl. Phannacol. 52: 177- 180. 
37. Kamdem, L., Siest, G. & Magdalou, J. (1982) Differential toxicity of aflatoxin B1 in 
male and female rats: Relationship with hepatic drug-metabolizing enzymes. 
Biochem. Phamarcol. 3 1: 3057-3062. 
38. Marasas, W.F.O. & Nelson, P.E. (1987) Aflatoxicosis. In: Mycotoxicology: 
Introduction to the Mycology, Plant Pathology, Chemistry, Toxicology, and 
Pathology of Natural Occuring Mycotoxicosis in Animals and Man, pp. 25-3 1 ,  
Pennsylvania State University Press, University Park, PA. 
84 
39. Shank, R.C. & Wogan, G.N. (1966) Acute effects of aflatoxin B 1 on liver 
composition and metabolism in the rat and duckling. Toxicol. Appl. Phannacol. 9: 
468-476 . 
40. Donaldson, W.E., Tung, H. & Hamilton, P.B .  (1972) Depression of fatty acid 
synthesis in chick liver (Gallus Domesticus) by aflatoxin. Comp. Biochem. 
Physiol. , 41B :  843.-847. 
41. Tung, H. , Donaldson, W.E. & Hamilton, P.B .  (1972) Altered lipid transport during 
aflatoxicosis. Toxicol. Appl. Phannacol. 22: 97- 104. 
42. Kato, R. Onado, K. & Omoru, Y. 1969. Effect of aflatoxin B 1 on the incorporation 
of 14c-acetate into cholesterol by rat liver. Specialia 25: 1026. 
43. Clifford, I.I. & Rees, K.R. (1 967) The action of aflatoxin B 1 on the rat liver. 
Biochem. J. 102: 65-75. 
44. Osborne, D.J. & Hamilton, P.B .  ( 198 1 ) Steatorrhea during aflatoxicosis in chickens. 
Poultry Sci. 60: 1398-1402. 
45. B lack, H.S., Smith, J.D. ,  Austin, B.J. & Rauschkolb, E.W. (1 970) Effect of 
aflatoxin B 1 on the in vitro incorporation of C-acetate into human skin lipids. 
Experientia 26: 1292- 1293. 
46. Bhattacharya, R.K., Firozi, P.F. & Aboobaker, V.S. (1 984) Factors modulating the 
formation of DNA adduct by aflatoxin B 1 . Carcinogenesis 5: 1359- 1362. 
47. Bhattacharya, R.K., Francis, A.R. & Shetty, T.K. (1 987) Modifying role of dietary 
factors on the mutagenicity of aflatoxin B 1 : In vitro effect of vitamins. Mutation 
Res. 1 88:  121 - 128. 
48. Bhattacharya, R.K., Prabhu, A.L. & Aboobaker, V.S. (1989) In vivo effect of 
dietary factors on the molecular action of aflatoxin B 1 : role of vitamin A on the 
catalytic activity of liver fractions. Cancer Lett. 44: 83-88 . 
49. Firozi, P.F. ,  Aboobaker, V.S. & Bhattacharya, R.K. (1 987) Action of vitamin A on 
DNA adduct formation by aflatoxin B 1 in a microsome catalyzed reaction. Cancer 
Lett. 34: 213-220. 
50. Raina, V. & Gurtoo, H.L. ( 1985) Effects of vitamins A, C, and E on aflatoxin B I  -
induced mutagenesis in Salmonella typhimurium TA-98 and T A- 100. Teratogen. 
Carcinogen. Mutagen. 5: 29-40. 
5 1 . Chen, J., Goetchius, M.P., Campbell, T.C. & Combs, G.F. Jr. ( 1982) Effects of 
dietary selenium and vitamin E on hepatic mixed-function oxidase activities and in 
vivo covalent binding of aflatoxin B 1 in rats. J. Nutt. 1 12: 324-331 . 
85 
52. Campbell, T .C., Hayes, J.R. & Newbeme, P.M. (1978) Dietary lipotropes, hepatic 
microsomal mixed-function oxidase activities, and in vivo covalent binding of 
aflatoxin B 1 in rats. Cancer Res. 38:  4569-4573. 
53. Rogers, A.E. & Newbemc, P.M. (1969) Aflatoxin B1 carcinogenesis in lipotrope­
deficient rats. Cancer Res. 29: 1965-1972. 
54. Shctty, T.K., Francis, A.R. & Bhattacharya, R.K. (1989) Modifying role of dietary 
factors on the mutagenicity of aflatoxin B 1: in vitro effect of sulphur-containing 
amino acids. Mutation Res. 222: 403-407. 
55. Marzuki, A. & Norred W.P. (1984) Effects of saturated and unsaturated dietary fat 
on aflatoxin B 1 metabolism. Fd. Chem. Toxic. 22: 383-389. 
56. Newbeme, P.M., Weigen, J. & Kula, N. (1979) Effects of dietary fat on hepatic 
mixed-function oxidascs and hepatocellular carcinoma induced by aflatoxin B 1 in 
rats. Cancer Res. 39: 3986-3991. 
57. Dirr, H. W. ( 1987) Effects of hydrogen ion and fatty acid concentrations on the 
binding of aflatoxin B1 to human albumin. Biochem. International 14 :  727-733. 
58. Dirr, H.W. & Schabon, J.C. (1986) Aflatoxin Bl transpon in rat blood plasma. 
Binding to albumin in vivo and in vitro and spectrofluorimetric studies into the 
nature of the interaction. Biochem. Biophy. Acta 881: 383-390. 
59. Francis, A.R., Shetty, T.K. & Bhattacharya, R.K. (1988) Modifying role of dietary 
factors on the mutagenicity of aflatoxin B 1: In vitro effect of trace elements. 
Mutation Res. 199: 85-93. 
60. Pegram, R.A., Allaben, W.T. & Chou, M.W. (1989) Effect of caloric restriction on 
aflatoxin B 1-DNA adduct fonnation and associated factors in Fischer 344 rats: 
Preliminary findings. Mech. Ageing Dev. 48: 167-177. 
61. Salbe, A.O. & Bjeldanes, L.F. (1989) Effect of diet and route of administration on 
the DNA binding of aflatoxin B1 in the rat. Carcinogenesis 10: 629-634. 
62. Grahams, S (1983) Results of case-control studies of diet and cancer in Buffalo, 
New York. Cancer Res. 43 (suppl.): 2409s-24 1 3s. 
63. Dashwood, R.H., Arbogast, D.N., Fong, A.T., Pereira, C., Hendricks, J.D. & 
Bailey, G.S. (1989) Quantitative inter-relationships between aflatoxin B 1 
carcinogen dose, indole-3-carbinol anti-carcinogen dose, target organ DNA 
adduction and final tumor response. Carcinogenesis 10: 175-181. 
64. Chang, Y. & Bjeldanes, L.F. (1987) R-goitrin- and BRA induced modulation of 
aflatoxin B t binding to DNA and biliary excretion of thiol conjugates in rats. 
Carcinogenesis 8: 585-590. 
86 
65. Bhattacharya, R.K. & Firozi, P.F. (1988) Effect of plant flavonoids on microsome 
catalyzed reactions of aflatoxin BI leading to activation and DNA adduct formation. 
Cancer Lett 39: 85-91. 
66. Francis, A.R., Shetty, T.K. & Bhattacharya, R.K. (1989) Modifying role of dietary 
factors on the mutagenicity of aflatoxin B 1: in vitro effect of plant flavonoids. 
Mutation Res. 222: 393-401. 
67. San, R.H.C. & Chan, R.1.M. (1987) Inhibitory effect of phenolic compounds on 
aflatoxin B 1 metabolism and induced mutagenesis. Mutation Res. 177: 229-239. 
68. Goeger, D.E., Shelton, D.W., Hendricks, J.D., Pereira, C. & Bailey, G.S. ( 1988) 
Comparative effect of dietary butylated hydorxyanisole and 6-naphthoflavone on 
aflatoxin BI metabolism, DNA adduct formation, and carcinogenesis in rainbow 
trout. Carcinogenesis 9: 1793-1800. 
69. Loury, D.J., Hsieh, D.P.H. & Byard, J.L. (1984) The effect of phenobarbital 
pretreatment on the metabolism, covalent binding, and cytotoxicity of aflatoxin B 1 
in primary cultures of rat hepatocytes. J. Toxicol. Environ. Health 13: 145-159. 
70 Lotlikar, P.O., Raj, H.G., Bohm, L.S., Ho, L.L., Jhee, E., Tsuji, K., & Gopalan, P� 
( 1989) A mechanism of inhibition of aflatoxin B 1-D NA binding in the liver by 
phenobarbital pretreatment of rats. Cancer Res. 49: 951-9�7. 
71. Toskulkao, C. & Glinsukon, T. (1986) Effect of ethanol on the in vivo covalent 
binding and in vitro metabolism of aflatoxin BI in rats. Toxicol. Letter 30: 151-
157. 
72. Chentancz, T. Patradilok, P., Glinsukon, T. & Plyachaturawat, P. ( 1 988) Effects of 
cortisol pretreatment on the acute hepatotoxicity of aflatoxin B 1. Toxicol. Letter 42: 
237-248. 
73. Leibovitz, B. (1984) Camitine: an overview. In: Carnitine. The Vitamin Bt 
Phenomenon, pp.15-23, Dell Publishing Co., Inc., New York. 
74. Fritz, I.B. (1959) Action of carnitinc in long chain fatty acid oxidation by liver. 
American J. Physiology 197: 297-304. 
75. Engel, A.G. &.Engelini, C. (1973) Carnitine deficiency of human skeletal muscle 
with associated lipid storage myopathy: a new syndrome. Science 179: 899-902. 
76. Leibovitz, B.E. (1987) Carnitine. Nutrition Update 2(3): 1-15. 
77. Borum, P.R. (1983) Carnitine. Ann. Rev. Nutt. 3: 233-259. 
78. Tanpaichitr, V. & Broquist, H.P. (1974) Site of carnitine biosynthesis in the rat. J. 
Nutr. 104: 1669-73. 
79. Rebouche, C.J. & Engel, A.G. (1980) Tissue distribution of carnitine biosynthetic 
enzymes in man. Biochim. Biophys. Acta 630: 22-29. 
87 
80. Frenkel, R.A. & McGarry, J.D. (eds.) (1980) In: Camitine Biosynthesis, 
Metabolism, and Functions, pp. 1 -352, Academic Press, New York. 
8 1 .  Kaiser, E. & Lohninger, A. (eds.) (1987) In: Carnitine--Its Role in Lung and Heart 
Disorders. Proceeding of a satellite symposium on the occasion of the Central 
European Congress for Anesthesiology (ZAK), Graz (Austria), September 13, 
1985, pp. 1 - 137, Karger, New York. 
82. Guzman, M. & Geelen, M.J.H. (1988) Shon-term inhibition of carnitine 
palmitoyltransferase I activity in rat hepatocytes incubated with ethanol. Biochem. 
Biophy. Res. Commun. 154: 682-687. 
83. Brothers, R.A.R. ( 1989) Effect of carnitine on the disposition of alcohols. Ph.D. 
Dissertation, The University of Tennessee. 
84. Senekowitsch, R., Lohninger, A., Kriegel, H. , Stanick, H., Krieglsteiner, H. & 
Kaiser, E. ( 1987) Protective effects of camitine on adriamycin toxicity to heart. 
In: Carnitine--Its Role in Lung and Heart Disorders. Proceeding of a satellite 
symposium on the occasion of the Central European Congress for Anesthesiology 
(ZAK), Graz (Austria), September 13, 1985, (Kaiser, E. & Lohninger: A. , eds.), 
pp. 1 26- 137,  Karger, New York. 
85 . Strohm, G.H. II, Payne, C.M., Alberts, D.S., Peng, Y., Moon, T.E., Bahl, J.J. & 
Bressler, R. (1982) Cardiotoxic effects of doxorubicin with and without carnitine. 
Arch. Pathol. Lab. Med 106: 1 8 1 - 1 85. 
86. Gerber, N., Dickerson, R.G. and Harland R.C. ( 1979) Reye-like syndrome 
associated with vaproic acid J. Pediatr. 95: 14�- 144. 
87 . Rodriguez-Segade, S . ,  Pena, C.A., Tutor, J.C., Paz, J.M. , Fernandez, M.P., Rozas, 
I. & Rio, D.L. (1989 ) Carnitine deficiency associated with anticonvulsant therapy. 
Clinic. Chimic. Acta 1 8 1 :  175-1 82. 
88. Laub, M.C., Paetzke-Brunner, I. & Jaeger, G. ( 1986) Serum carnitine during valroic 
acid therapy. Epilepsia 27: 559-562. 
89. Quistad, G.B., Staiger, L.E. & Schooley, D.A. ( 1986) The role of carnitine in the 
conjugation of acidic zenobiotics. Drug Metab. Disposition 14: 52 1-525. 
90. Petroff, C.P. , Patt, H.H. & Nair, P.P. ( 1965) A rapid method for dissolving tissue 
for liquid scintillation counting. Intemat. J. Appl. Rad. Isotopes 16: 599-601 .  
9 1 .  Cederblad, G. & Lindstedt, S .  (1972) A method for determination of camitine in the 
picomole range. Clin. Chem. Acta 37: 235-243. 
92. Elleston, R.D. & Carraway, W.T. ( 1976) Lipids and lipoproteins. In : Fundamental 
of Clinical Chemistry (Tietz, N.W., ed.), pp. 492-496, WB Saunders Co, 
Philadelphia. 
93. Giegel, J.L. Ham, A.B. & Clema, W. ( 1975) Manual and semi-automated 
procedures for measurement of triglycerides in serum. Clin. Chem. 21 : 1575-
158 1 .  
88 
94. Glazer, R.I. & Weber, G. (197 1 )  Incorporation of 6-3H] glucose into lipid, protein, 
RNA and DNA of slices of differntiating rat cerebral cortex. J. Neurochem. 1 8: 
1569- 1579. 
95. Ceriotti, G. ( 1952) A microchemical determination of deoxyribonucleic acid J. Biol. 
Chem. 198 : 297-303. 
96. Lowry, 0.H., Rosebrough, N.J. , Farr, A.L. & Randall, R.J. ( 195 1 )  Protein 
measurement with the folin phenol reagent. J. Biol. Chem. 193 :  265-275. 
97. Stoloff, L. & Trager, W. (1965) Recommended decontamination procedures for 
aflatoxin. J. Assoc. Off. Anal. Chem. 48 : 68 1 -682. 
98. Fischbach, H. & Campbell, A.O. ( 1965) Note on detoxication of the aflatoxins. J. 
Assoc. Off. Anal. Chem. 48: 28. 
99. Castegnaro, M., Egmond, H.P.V., Paulsch, W.E. & Michelon, J. ( 1982) 
Limitations in protection afforded by gloves in laboratory handling of aflatoxins. J. 
Assoc. Off. Anal. Chem. 65: 1520- 1523. 
100. Berger, Robert ( 1987) Effects ofL-carnitine on ethanol metabolism. Ph.D. 
Dissertation, The U Diversity of Tennessee. 
101 .  Khan, L. & Bamji, M.S .  ( 1979) Tissue carnitine deficiency due to lysine 
deficiency: Triglyceride accumulation and concomitant impairment in fatty acid 
oxidation. J. Nutr. 109: 24-3 1 .  
102. Lennon, D.L.F. & Mance, M.J. ( 1986) Interorgan cooperativity in camitine 
metabolism in trained state. J. Appl. Physiol. 60: 1659- 1664. 
103. Olson, A.L., Nelson, S .E. & Rebouche, C.J. ( 1989) Low carnitine intake and 
altered lipid metabolism in infants. J. Clin. Nutr. 49: 624-628. 
104. Slonim, A.E., Borum, P.R., & Tanaka, K. ( 198 1)  Dietary-dependent camitine 
deficiency as a cause of nonketotic hypoglycemia in an infant. J. Pediatr. 99 :55 1 -
556. 
105. Schrager, T.F., Newberne, P.M., Pikul, A.H. & Groopman, J.D. ( 1990) 
Aflatoxin-DNA adduct formation in chronically dosed rats fed a choline-deficient 
diet. Carcinogenesis 1 1 : 177-1 80. 
106. Corredor, C., Mansbach, C. & Bressler, R. (1967) Camitine depletion in the 
choline-deficient state. Biochim. Biophys. Acta 144: 366-374. 
89 
107. Vickers, S. , Duncan, C.A.H., White, S.D.,  Ramjit, H. G., Smith, J.L. ,  Walker, 
R.W., Flynn, H. & Arison, B.H. (1985) Camitine and glucuronic acid conjugates 
of pivalic acid. Xenobiotica 15: 453 -458. 
90 
APPENDIX 
91 
A-3, 1 Dual Radioactivity Count, 
DUAL LABEL DPM (LS 1801/3801) 
Setting Up A Dual Label OPM Program 
While the calculations for Dual Label DPM are much 
more difficult than for single label , there is very little dif. 
ference for the operator in the setup of the program. A 
review of the single label DPM section is recommended 
before continuing. Figure 1 0-6 shows the series of ques­
tions as they occur on the LS-3801 CRT. LS 1801 ques­
tions are identical but appear on the pri nter. The setup 
for the Dual Label DPM programs is the same as the 
single label DPM except that four questions require an 
answer for isotope 2 as well as isotppe 1 in the dual label 
programs. These questions are: Unknown Normalization 
Factor, Unknown Units, Half Life, and Standard DPM. 
Setting Up The User Fite 
The quench curve you store will determine the accuracy 
of all the DPM answers you get from this program. It is 
therefore recomended that you set up rigerous count ing 
conditions for the standards. These can be relaxed for 
the unknowns as you see fi t. Count the samples long 
enough to reach a 0.5% to 1% 2sigma statistical l imit 
(160,000 to 40,000 total counts). Turn AOC on and take 
multiple H#'s (4 to 6). Channel 1 must be used for isotope 
1, the lower energy isotope and Channel 2 must be used 
for isotope 2, the higher energy isotope. ACM , if 
avai lable, should be used. 
The channel · sett ings are determined by the two 
isotopes being counted. Usually, Channel 1 (the lower 
energy isotope) is set to cover the entire isotope rangq 
(0-400 for 1H ,  for example). Channel 2 (the higher 
energy isotope) is set so the lower window is the same 
as the uppet window for the lower energy isotope. The 
Channel 2 upper window is set for the isotope 2 end point 
(400-670 for • •c in a 3Hl'·C dual label} .  Spectrum 
Search can be used to determine window setti ngs for 
unknown isotopes. 
Counting The Standards and Unknown!t 
For Dual Label DPM programs you must have two sets 
of standards, one for each isotope to be counted . Place 
the lower energy isotope standard set in  a rack first. 
Leave a space and put in the higher energy isotope 
standara ·�et. Isotope 1 is always the lower energy 
isotope and must be counted first. Isotope 2 is always the 
higher energy isotope and must be counted second. 
After placing the Isotope 2 standards in a rack, leave a 
space and follo_w that with the unknowns (Figure 10·7). 
If no unknowns are fo be counted immediately, put in a 
rack with a Halt card. Refer to 10.2 for preparing quench 
curve!. 
Explanation Of Printouts 
The printout for Dual Label DPM reflects the increased 
complexity over Single Label DPM. However, the mean­
ings of the printout are the same (Figure 10-8) . First, the 
program summary is printed out. This is followed by the 
data for Isotope 1 and Isotope 2 standards. Notice here 
that two efficiencies are calculated for each isotope. One 
efficiency is the isotope i n  its own counting channel 
(isotope 1 counted in channel 1 or isotope 2 in channel 
2), and another efficiency is for the spillover of one 
isotope into the other isotope's counting channel (isotope 
1 counted in channel 2 or isotope 2 counted in chan nel 
1). (See Section 1 .7 and Chapter 5). This correct ion for 
four efficiencies leads to four EFFICIENCY CURVE 
CORRELATION TABLES and four sets of coefficients. 
However. this complexity is handled by the instrument 
so there is l itt le difference to the operator except for the 
printout. 
The printout for the unknowns follows the quench 
parameters. This printout includes the DPM for the two 
isotopes and four counting efficiencies for each sample 
(isotope 1 in channel 1, isotope 1 in  channel 2. iso�ope 
2 in channel 1 ,  and isotope 2 in channel 2). The ratio of 
isotope OPM's is also presented (Isotope 1/lsotope 2 and 
Isotope 2/lsotope 1) since this is often of interest in  dual 
label experiments. 
Source: Beckman LS 1801, 3801and 5801 Series Liquid Scintillation Systems Operating Manual, Beckman Instruments, Irving, CA. 
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A-3,2 Precaurionazy and Decontamination Procedures Purini Handlin& of Aflatoxins . 
Aflatoxins have been shown to be extremely toxic and carcinogenic to number of 
laboratory and domestic animals. Aflatoxin B 1 has been epidemiologically linked to human 
liver cancer. Therefore, stringent safety measures should be exercised to prevent contact or 
exposure with these toxins during handling. The following are the safety procedures and 
recommendations as described by Stoloff et al. ( 1965), Fischbach et al. ( 1965), and 
Castegnaro et al. ( 1982). 
HANDLING OF DRY TOXINS 
1 .  If possible, employ aflatoxins in solution since dry aflatoxins are electrostatic. 
2. Always handle dry toxins under hoods that are properly ventilated and filtered. 
3. Face masks and disposable rubber gloves should be worn. 
DECONTAMINATION 
a) Spilla&e 
1 .  Cover area completly with 5-6% sodium hypochlorite (full strength chlorox, an household bleach) dispensed from a wash-bottle. 
2. If the surface cannot be wetted completely, cover the spillage with paper towels, and 
wet the towels entirely with the bleach. 
3. The amount of bleach used should be more than one-tenth of the volume of the spillage. 
4. Contact time must be more than 30 seconds. 
5. Wipe the surface off with paper towels. 
6. Check area with UV lamp to ensure thorough decontamination is attained. 
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<Continued) . 
b) Dust and powdered aflatoxins 
1 .  For inaccessible areas and before regular cleaning, vacuum the dust and treat the 
contents of the vacuum bag with 5% N aOCl before disposing the bag. 
2. Same treatment as for spillage if possible. 
3. If not, wipe the surface with paper towels soaked in 5% NaOCl. 
c) Hoods 
1 .  Wipe the hoods regularly with 5% NaOCl. 
2. At the end of the working day, decontaminate the hoods with chlorine gas produced by 
adding equal volume of 5% NaOCl and 6N HCl. 
3. Let the gas disperse for few minutes while the hood's door is shut. Exhaust overnight. 
d) Laboratmy wares 
1 .  Use 0.5% NaOCl for washing glass and other laboratory wares. 
2. Ensure the entire surf ace of the wares is wetted and soaked for at least 30 seconds. 
3. Soaking the wares in detergent + water for 8 hr could be used to substitute for the 
bleach. 
4. Rinse with acetone before drying. 
5. Before disposing the solutions used for soaking, add full strength NaOCl (aLout one­
tenth the volume of the soaking solutions). 
Personnel 
1 .  Always use rubber gloves and protective masks when handling aflatoxins. Never 
reused the gloves or masks. 
2. Wear lab coat to prevent direct contact of possible spillage and dry toxins with clothes. 
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<Continued} . 
3. Rubber gloves provide better protection then vinyl gloves for handling of aflatoxins in 
dimethyl sulfoxide solution. 
. 4 . .  Aflatoxin in chloroform can penetrate both rubber and vinyl gloves, therefore; 
immediately change the gloves if the solution spilled onto the gloves. 
5. If practical, wear thick or double pair of thin rubber gloves. 
6. When skin is contaminated, wash it with 5% NaOCl before washing with soap and 
water. 
7. Sodium perborate with soap can be used if the skin is sensitive to the bleach. 
8. If the mouth is contaminated, gaggle a mixed solution of 1 % sodium pcrborate and 1 % 
sodium bicarbonate in water. 
9. Contaminated garments should be soaked in 1 % NaOCl (for cellulose fabrics) or 5% 
sodium carbonate solution (for cotton or rayon fabrics) for 1 hr before laundering. 
Disposal of Contaminated Materials and Samples 
1. Keep all samples and used gloves and masks in tightly closed containers, for examples 
cans, jars, or plastic bags. 
2. Bum the containers. 
3. If burning is not possible, soaked the toxic materials in 5% NaOCl for 1/2 hr minimum. 
4. Mixing might be necessary to get thorough soaking. 
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Table A-4. 1 Percent Change in Total Lipid and Triglyceride Content due to 
Diet and AFB 1 Treahnents in Rats of Experiment 1 (6 h Post-AFB 1). 
LIVER PLASMA 
Total Lipids (%) Triglycerides (%) Total Lipids (%) Triglycerides (%) 
Nsc1 - NsA2 7.9 
NSC - Csc3 2.0 
NSC - CSA4 1 .6 
NSA - CSC 9.2 
NSA - CSA 8.9 
CSC - CSA 0.3 
1 NSC = Nonsupplemented Control 
2N SA = Nonsupplemented AFB 1 ; 
3csc = Carnitine Supplemented; 
4CSA = Carnitine Supplement AFB 1 . 
1 8 .7 17 .3 30.5 
3 .8 20.6 37.2 
1 1 . 1  6.4 6.9 
12 .5 4. 1 9 .6 
6.4 1 3 .2 34.0 
7 .0 1 8 .0 48.2 
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